The beach-chair position (BCP) is commonly used for both arthroscopic and open shoulder surgery. This technique positions the shoulder in an anatomical upright position, facilitating shoulder access and visualization.¹ Compared with the lateral decubitus position, the BCP also improves airway access, reduces bleeding, and lessens the risk for brachial plexus injury.²

Despite the advantages of using the BCP, there have been multiple reports of catastrophic neurologic complications, including severe brain damage and death, in relatively healthy patients without any known risk factors.^3-6 The definitive etiology of these complications remains unclear, but it has been hypothesized that BCP use may be an independent risk factor for cerebrovascular ischemia,^1,5-16 as the upright position can cause hypotension leading to increased risk for cerebral hypoperfusion.^7-11,17 Reducing cerebral perfusion pressure below critical thresholds may result in permanent neurologic injury.^4-6,14 Therefore, monitoring of cerebral perfusion and optimization of intraoperative cerebral oxygenation have been recommended to help avoid potential neurologic complications. However, a direct relationship between intraoperative cerebral desaturation events (CDEs) and postoperative neurocognitive deficits has not been definitively established.^1,9-12

To put into perspective the importance of detecting and preventing CDEs and neurologic complications, we can consider the incidence of fatal pulmonary embolism associated with total joint arthroplasty. Although the incidence is very low, about 0.1% to 2.0%, some form of venous thromboembolism prophylaxis is the standard of care for helping prevent this serious complication. Similarly, catastrophic neurologic complications of upright shoulder arthroscopy are very rare, but it is still important to consider measures that help minimize them.

We reviewed the literature for the incidence of postoperative neurocognitive deficits, number of reported neurocognitive complications, and incidence of intraoperative CDEs in patients who underwent arthroscopic shoulder surgery in the BCP.

Methods

Dr. Salazar and Dr. Hazel independently searched the Medline, Cochrane, and Embase databases for case series, prospective studies, and cohort studies that reported neurocognitive complications associated with the BCP and the incidence of intraoperative CDEs. The authors used beach chair, desaturation, near infrared spectroscopy, and shoulder as medical subject headings (MeSH). In addition, bibliographies of retrieved articles were checked for studies that the search terms may have missed. Eighty-one publications were identified and reviewed for possible inclusion.

Next, the same 2 authors reviewed the titles and abstracts for relevance and determined which articles had potential to contribute to the study. Only English-language publications were considered for inclusion. To review the incidence of postoperative neurocognitive deficits, we included only those studies with more than 25 patients, documentation of postoperative complications, and arthroscopic shoulder surgery performed with the patient in the seated, semi-upright, or BCP. Only studies with at least 25 patients were used in order to increase the power and improve the level of evidence. To review reported cases of neurocognitive complications, we included all relevant case reports and case series. To review the incidence of intraoperative CDEs and investigate their relationship with postoperative neurocognitive deficits, we included studies that reported on use of intraoperative cerebral perfusion monitoring. Modalities used in these studies included near infrared spectroscopy, electroencephalography, and invasive blood pressure monitoring calculated at the brain level. Studies were excluded if they did not involve arthroscopic shoulder surgery or were not conducted with human subjects.

Information recorded for each study included general information such as author and publication year, type of study, number of patients enrolled, type of intraoperative monitoring, anesthesia protocol, number of patients with CDEs, and number of patients with neurocognitive complications after surgery.

Results

Our search identified 81 publications for potential inclusion. Our first aim was to identify the overall incidence of reported neurocognitive deficits after arthroscopic shoulder surgery with the patient in the BCP. We identified 10 studies (Table 1) that met the inclusion criteria. Among the 24,701 patients in these 10 studies, there was only 1 reported case of neurocognitive deficit after surgery, in a mixed prospective-retrospective study of 15,014 cases by Rohrbaugh and colleagues.18 The deficit they reported was an ischemic cerebral vascular accident. The 0.0067% incidence in their study demonstrates how rare the complication is. Two large retrospective studies (Ns = 4169 and 5177 patients) found no postoperative neurocognitive complications.^19,20 Only 3 studies performed formal postoperative cognitive testing. Salazar and colleagues²¹ used the Repeatable Battery for the Assessment of Neuropsychological Status before and after surgery, and Gillespie and colleagues⁸ and Lee and colleagues¹⁰ used the Mini–Mental State Examination before and after surgery. Total incidence of reported neurocognitive deficits from our review was 0.004% (1/24,701).

Our second aim was to review all reported cases of neurocognitive complications after arthroscopic shoulder surgery with the patient in the BCP. We identified 4 publications that fit our inclusion criteria (Table 2). Pohl and Cullen6 described 4 cases of ischemic brain injury after arthroscopic shoulder surgery with the patient in the BCP. Age range was 47 to 57 years. Specific intraoperative cerebral monitoring was not used. However, these patients had several episodes of intraoperative hypotension (systolic blood pressures, 80-90 mm Hg), measured with a traditional blood pressure cuff on the arm. In general, these patients had minimal cerebrovascular risk factors and no known preexisting cerebrovascular disease. Drummond and colleagues²² described an ischemic stroke in a 50-year-old man after arthroscopic subacromial decompression and open rotator cuff repair that resulted in unresolved right hemiplegia. Subsequent diagnostic investigation revealed an asymmetry of the circle of Willis resulting in limited flow to the left anterior and middle cerebral artery distributions. Bhatti and Enneking³ reported the case of a 64-year-old man who lost vision in the right eye immediately after arthroscopic rotator cuff repair. His vision improved spontaneously the next morning and continued to improve over the next 6 months—he regained 20/20 vision with some residual optic neuropathy.

Our third aim was to determine the incidence of intraoperative CDEs during arthroscopic shoulder surgery with the patient in the BCP. Incidence of CDEs varied widely among the 7 studies reviewed (Table 3). Minimum incidence of intraoperative CDE was 0% in a cohort of 30 patients,¹ and maximum incidence was 80% in a study of 61 patients,¹² all of whom underwent elective arthroscopic shoulder surgery in the BCP. Although there was wide variability in CDE incidence, the studies were consistent with respect to their definition of a CDE. Most authors used a decrease in regional cerebral tissue oxygen saturation of 20% or more from baseline, or an absolute value up to 55%, to define a CDE. None of the 7 studies reviewed reported a clinically significant adverse neurocognitive event.

Discussion

Of concern, there have been several surveys, case reports, and small case series of previously healthy patients who had no known risk factors, underwent arthroscopic shoulder surgery in the BCP, and developed unanticipated postoperative neurologic complications.^4-6,14 Beach-chair positioning during surgical procedures has been implicated as a contributing factor leading to cerebral hypoperfusion with potential for cerebral ischemia.^1,12,23 These changes in cerebral perfusion pressure are thought to be the major determinant of poor neurologic outcomes. Such reports have exposed the potential need for heightened vigilance, alternative anesthesia techniques, and improved monitoring, though the exact etiology of the central nervous system injuries in this patient population is incompletely understood and is likely multifactorial. Therefore, in this study we wanted to determine the incidence of postoperative neurocognitive deficits and review all reported cases of neurocognitive complications in patients who have undergone arthroscopic shoulder surgery in the BCP. In addition, we wanted to define the incidence of intraoperative CDEs and investigate their relationship with postoperative neurocognitive complications.

According to our review, the incidence of postoperative neurocognitive complications after surgery in the BCP is 0.004% (1/24,701). However, this finding is based only on what has been reported; the true incidence is not known. It is also important to note that the incidence of neurocognitive deficits after many other types of surgery is not known and that surgery itself may be a risk factor for postoperative neurocognitive deficits.²⁴ In their retrospective review of 15,014 patients who underwent arthroscopic shoulder surgery in the BCP at a single institution over an 11-year period, Rohrbaugh and colleagues18 found an overall postoperative complication rate of 0.37% and a 0.0067% incidence of neurocognitive deficits. One patient in the series was given a diagnosis of ischemic stroke on the basis of neurologic deficits that occurred 24 hours after surgery. Yadeau and colleagues²⁰ found no postoperative neurocognitive complications in a mixed prospective-retrospective study of 4169 patients—3000 identified retrospectively, 1169 prospectively—who underwent arthroscopic shoulder surgery in the BCP at an ambulatory surgery center. Pin-on and colleagues¹⁹ reported on a series of 5177 orthopedic and neurosurgical patients who underwent surgery in the BCP. In those who had arthroscopic shoulder surgery, intraoperative systolic blood pressures obtained from an arterial line referenced to heart level decreased a mean (SD) of 14.4% (12.7%), whereas in those whose pressures were obtained from a noninvasive blood pressure cuff referenced to heart level decreased 19.3% (12.6%). However, the authors reported no incidence of postoperative stroke or neurologic deficits.

Although uncommon, perioperative cerebral ischemic accidents are potentially devastating for patients, their families, and the health care professionals involved. These events have tremendous economic, social, professional, and medicolegal implications, with perioperative stroke being particularly morbid. Perioperative stroke has a mortality rate of 60%, versus 15% to 46% for stroke in general.^25,26 In 2005, Pohl and Cullen⁶ published a landmark article on a series of 4 relatively healthy middle-aged patients who were at low risk for stroke but had catastrophic neurocognitive complications (including 1 death) after arthroscopic shoulder surgery in the BCP. Bhatti and Enneking³ described a case of acute postoperative vision loss and ophthalmoplegia attributed to intraoperative hypotension leading to ischemia in a patient who underwent an elective shoulder arthroscopic procedure in the BCP. These reports prompted multiple investigations into the physiologic hemodynamic changes associated with surgery in the BCP and the treatment strategies used to improve patient safety.

In the normal physiologic state, the sympathetic nervous system is activated when a person assumes the seated position. The result is increased systemic vascular resistance and heart rate alterations to maintain cardiac output and mean arterial pressure. In anesthetized patients, this response is blunted by the vasodilatory effects of intravenous and volatile anesthetics. Multiple studies have demonstrated substantial hemodynamic changes in both awake and anesthetized patients during the maneuver from the supine position to the seated position^1,27,28; these changes include diminished cardiac index, stroke volume, and arterial pressure.¹⁷ The data underscore the need for attentiveness and accurate monitoring of cerebral perfusion when the transition is made from the supine position to the BCP, particularly in the early phase of surgery and in high-risk patients.

Knowledge of these hemodynamic changes has led several authors to recommend additional intraoperative monitoring of cerebral perfusion. Monitoring techniques have included use of invasive blood pressure monitoring adjusted to brain level, cerebral oximetry using near infrared spectroscopy, and electroencephalography. However, the clinical relevance of intraoperative CDEs in isolation is not well understood.^1,6,7,23 In addition, cost and availability of additional advanced monitoring likely factor into why it is not more commonly used. For this patient population, the severity, frequency, and duration of desaturation that causes cerebral ischemia and the relationship with postoperative neurocognitive deficits remain undefined.

The incidence of CDEs in patients being monitored with near infrared spectroscopy while undergoing elective arthroscopic shoulder surgery in the BCP varies widely, from 0% to 80% (mean, 41%).^{1,4,7,10,12,21} Magnitude and duration of cerebral ischemia required to produce neurocognitive dysfunction in this patient population remain unidentified as well. In conscious patients, a 20% reduction in frontal lobe oxygenation is associated with clinical manifestations of cerebral hypoperfusion, such as syncope.^15,29 As none of the patients in the studies we reviewed experienced any sort of deficit, we cannot definitively state there is a correlation between CDE occurrence and neurocognitive deficit.

One limitation of our investigation is that it was a systemic review, and thus there was substantial heterogeneity in the methods and designs of the studies included in the analysis. Among the different series, there was variability in multiple aspects of the study design, including type of anesthetic, patient inclusion criteria, type of surgery, type of intraoperative cerebral perfusion monitoring, and type of neurocognitive testing. As a result, comparing the groups was difficult, and the generalizability of our findings may be limited. In addition, it is difficult to accurately establish incidence and comprehensively review these events because of the paucity of literature.

Conclusion

Neurocognitive complications after shoulder arthroscopy with the patient in the BCP are extremely rare but potentially devastating events that can affect healthy patients with no preexisting cerebrovascular risk factors. Our review indicated the incidence of permanent neurologic deficit after arthroscopy in the BCP may be as low as 0.004%. The exact etiology of such complications is not clear. Basic science research and large prospective studies are needed to identify the clinically relevant thresholds of magnitude, duration, and frequency of intraoperative CDEs in order to establish their relationship with postoperative neurocognitive complications. Such large studies may also elucidate modifiable patient-specific risk factors and establish the most sensitive, safe, and cost-effective intraoperative monitoring tools. Current literature suggests that accurate intraoperative monitoring of cerebral perfusion, alternatives to general anesthesia, and prudent use of intraoperative blood pressure control may improve patient safety.

The beach-chair position (BCP) is commonly used for both arthroscopic and open shoulder surgery. This technique positions the shoulder in an anatomical upright position, facilitating shoulder access and visualization.¹ Compared with the lateral decubitus position, the BCP also improves airway access, reduces bleeding, and lessens the risk for brachial plexus injury.²

Despite the advantages of using the BCP, there have been multiple reports of catastrophic neurologic complications, including severe brain damage and death, in relatively healthy patients without any known risk factors.^3-6 The definitive etiology of these complications remains unclear, but it has been hypothesized that BCP use may be an independent risk factor for cerebrovascular ischemia,^1,5-16 as the upright position can cause hypotension leading to increased risk for cerebral hypoperfusion.^7-11,17 Reducing cerebral perfusion pressure below critical thresholds may result in permanent neurologic injury.^4-6,14 Therefore, monitoring of cerebral perfusion and optimization of intraoperative cerebral oxygenation have been recommended to help avoid potential neurologic complications. However, a direct relationship between intraoperative cerebral desaturation events (CDEs) and postoperative neurocognitive deficits has not been definitively established.^1,9-12

To put into perspective the importance of detecting and preventing CDEs and neurologic complications, we can consider the incidence of fatal pulmonary embolism associated with total joint arthroplasty. Although the incidence is very low, about 0.1% to 2.0%, some form of venous thromboembolism prophylaxis is the standard of care for helping prevent this serious complication. Similarly, catastrophic neurologic complications of upright shoulder arthroscopy are very rare, but it is still important to consider measures that help minimize them.

We reviewed the literature for the incidence of postoperative neurocognitive deficits, number of reported neurocognitive complications, and incidence of intraoperative CDEs in patients who underwent arthroscopic shoulder surgery in the BCP.

Methods

Dr. Salazar and Dr. Hazel independently searched the Medline, Cochrane, and Embase databases for case series, prospective studies, and cohort studies that reported neurocognitive complications associated with the BCP and the incidence of intraoperative CDEs. The authors used beach chair, desaturation, near infrared spectroscopy, and shoulder as medical subject headings (MeSH). In addition, bibliographies of retrieved articles were checked for studies that the search terms may have missed. Eighty-one publications were identified and reviewed for possible inclusion.

Next, the same 2 authors reviewed the titles and abstracts for relevance and determined which articles had potential to contribute to the study. Only English-language publications were considered for inclusion. To review the incidence of postoperative neurocognitive deficits, we included only those studies with more than 25 patients, documentation of postoperative complications, and arthroscopic shoulder surgery performed with the patient in the seated, semi-upright, or BCP. Only studies with at least 25 patients were used in order to increase the power and improve the level of evidence. To review reported cases of neurocognitive complications, we included all relevant case reports and case series. To review the incidence of intraoperative CDEs and investigate their relationship with postoperative neurocognitive deficits, we included studies that reported on use of intraoperative cerebral perfusion monitoring. Modalities used in these studies included near infrared spectroscopy, electroencephalography, and invasive blood pressure monitoring calculated at the brain level. Studies were excluded if they did not involve arthroscopic shoulder surgery or were not conducted with human subjects.

Information recorded for each study included general information such as author and publication year, type of study, number of patients enrolled, type of intraoperative monitoring, anesthesia protocol, number of patients with CDEs, and number of patients with neurocognitive complications after surgery.

Results

Our search identified 81 publications for potential inclusion. Our first aim was to identify the overall incidence of reported neurocognitive deficits after arthroscopic shoulder surgery with the patient in the BCP. We identified 10 studies (Table 1) that met the inclusion criteria. Among the 24,701 patients in these 10 studies, there was only 1 reported case of neurocognitive deficit after surgery, in a mixed prospective-retrospective study of 15,014 cases by Rohrbaugh and colleagues.18 The deficit they reported was an ischemic cerebral vascular accident. The 0.0067% incidence in their study demonstrates how rare the complication is. Two large retrospective studies (Ns = 4169 and 5177 patients) found no postoperative neurocognitive complications.^19,20 Only 3 studies performed formal postoperative cognitive testing. Salazar and colleagues²¹ used the Repeatable Battery for the Assessment of Neuropsychological Status before and after surgery, and Gillespie and colleagues⁸ and Lee and colleagues¹⁰ used the Mini–Mental State Examination before and after surgery. Total incidence of reported neurocognitive deficits from our review was 0.004% (1/24,701).

Our second aim was to review all reported cases of neurocognitive complications after arthroscopic shoulder surgery with the patient in the BCP. We identified 4 publications that fit our inclusion criteria (Table 2). Pohl and Cullen6 described 4 cases of ischemic brain injury after arthroscopic shoulder surgery with the patient in the BCP. Age range was 47 to 57 years. Specific intraoperative cerebral monitoring was not used. However, these patients had several episodes of intraoperative hypotension (systolic blood pressures, 80-90 mm Hg), measured with a traditional blood pressure cuff on the arm. In general, these patients had minimal cerebrovascular risk factors and no known preexisting cerebrovascular disease. Drummond and colleagues²² described an ischemic stroke in a 50-year-old man after arthroscopic subacromial decompression and open rotator cuff repair that resulted in unresolved right hemiplegia. Subsequent diagnostic investigation revealed an asymmetry of the circle of Willis resulting in limited flow to the left anterior and middle cerebral artery distributions. Bhatti and Enneking³ reported the case of a 64-year-old man who lost vision in the right eye immediately after arthroscopic rotator cuff repair. His vision improved spontaneously the next morning and continued to improve over the next 6 months—he regained 20/20 vision with some residual optic neuropathy.

Our third aim was to determine the incidence of intraoperative CDEs during arthroscopic shoulder surgery with the patient in the BCP. Incidence of CDEs varied widely among the 7 studies reviewed (Table 3). Minimum incidence of intraoperative CDE was 0% in a cohort of 30 patients,¹ and maximum incidence was 80% in a study of 61 patients,¹² all of whom underwent elective arthroscopic shoulder surgery in the BCP. Although there was wide variability in CDE incidence, the studies were consistent with respect to their definition of a CDE. Most authors used a decrease in regional cerebral tissue oxygen saturation of 20% or more from baseline, or an absolute value up to 55%, to define a CDE. None of the 7 studies reviewed reported a clinically significant adverse neurocognitive event.

Discussion

Of concern, there have been several surveys, case reports, and small case series of previously healthy patients who had no known risk factors, underwent arthroscopic shoulder surgery in the BCP, and developed unanticipated postoperative neurologic complications.^4-6,14 Beach-chair positioning during surgical procedures has been implicated as a contributing factor leading to cerebral hypoperfusion with potential for cerebral ischemia.^1,12,23 These changes in cerebral perfusion pressure are thought to be the major determinant of poor neurologic outcomes. Such reports have exposed the potential need for heightened vigilance, alternative anesthesia techniques, and improved monitoring, though the exact etiology of the central nervous system injuries in this patient population is incompletely understood and is likely multifactorial. Therefore, in this study we wanted to determine the incidence of postoperative neurocognitive deficits and review all reported cases of neurocognitive complications in patients who have undergone arthroscopic shoulder surgery in the BCP. In addition, we wanted to define the incidence of intraoperative CDEs and investigate their relationship with postoperative neurocognitive complications.

According to our review, the incidence of postoperative neurocognitive complications after surgery in the BCP is 0.004% (1/24,701). However, this finding is based only on what has been reported; the true incidence is not known. It is also important to note that the incidence of neurocognitive deficits after many other types of surgery is not known and that surgery itself may be a risk factor for postoperative neurocognitive deficits.²⁴ In their retrospective review of 15,014 patients who underwent arthroscopic shoulder surgery in the BCP at a single institution over an 11-year period, Rohrbaugh and colleagues18 found an overall postoperative complication rate of 0.37% and a 0.0067% incidence of neurocognitive deficits. One patient in the series was given a diagnosis of ischemic stroke on the basis of neurologic deficits that occurred 24 hours after surgery. Yadeau and colleagues²⁰ found no postoperative neurocognitive complications in a mixed prospective-retrospective study of 4169 patients—3000 identified retrospectively, 1169 prospectively—who underwent arthroscopic shoulder surgery in the BCP at an ambulatory surgery center. Pin-on and colleagues¹⁹ reported on a series of 5177 orthopedic and neurosurgical patients who underwent surgery in the BCP. In those who had arthroscopic shoulder surgery, intraoperative systolic blood pressures obtained from an arterial line referenced to heart level decreased a mean (SD) of 14.4% (12.7%), whereas in those whose pressures were obtained from a noninvasive blood pressure cuff referenced to heart level decreased 19.3% (12.6%). However, the authors reported no incidence of postoperative stroke or neurologic deficits.

Although uncommon, perioperative cerebral ischemic accidents are potentially devastating for patients, their families, and the health care professionals involved. These events have tremendous economic, social, professional, and medicolegal implications, with perioperative stroke being particularly morbid. Perioperative stroke has a mortality rate of 60%, versus 15% to 46% for stroke in general.^25,26 In 2005, Pohl and Cullen⁶ published a landmark article on a series of 4 relatively healthy middle-aged patients who were at low risk for stroke but had catastrophic neurocognitive complications (including 1 death) after arthroscopic shoulder surgery in the BCP. Bhatti and Enneking³ described a case of acute postoperative vision loss and ophthalmoplegia attributed to intraoperative hypotension leading to ischemia in a patient who underwent an elective shoulder arthroscopic procedure in the BCP. These reports prompted multiple investigations into the physiologic hemodynamic changes associated with surgery in the BCP and the treatment strategies used to improve patient safety.

In the normal physiologic state, the sympathetic nervous system is activated when a person assumes the seated position. The result is increased systemic vascular resistance and heart rate alterations to maintain cardiac output and mean arterial pressure. In anesthetized patients, this response is blunted by the vasodilatory effects of intravenous and volatile anesthetics. Multiple studies have demonstrated substantial hemodynamic changes in both awake and anesthetized patients during the maneuver from the supine position to the seated position^1,27,28; these changes include diminished cardiac index, stroke volume, and arterial pressure.¹⁷ The data underscore the need for attentiveness and accurate monitoring of cerebral perfusion when the transition is made from the supine position to the BCP, particularly in the early phase of surgery and in high-risk patients.

Knowledge of these hemodynamic changes has led several authors to recommend additional intraoperative monitoring of cerebral perfusion. Monitoring techniques have included use of invasive blood pressure monitoring adjusted to brain level, cerebral oximetry using near infrared spectroscopy, and electroencephalography. However, the clinical relevance of intraoperative CDEs in isolation is not well understood.^1,6,7,23 In addition, cost and availability of additional advanced monitoring likely factor into why it is not more commonly used. For this patient population, the severity, frequency, and duration of desaturation that causes cerebral ischemia and the relationship with postoperative neurocognitive deficits remain undefined.

The incidence of CDEs in patients being monitored with near infrared spectroscopy while undergoing elective arthroscopic shoulder surgery in the BCP varies widely, from 0% to 80% (mean, 41%).^{1,4,7,10,12,21} Magnitude and duration of cerebral ischemia required to produce neurocognitive dysfunction in this patient population remain unidentified as well. In conscious patients, a 20% reduction in frontal lobe oxygenation is associated with clinical manifestations of cerebral hypoperfusion, such as syncope.^15,29 As none of the patients in the studies we reviewed experienced any sort of deficit, we cannot definitively state there is a correlation between CDE occurrence and neurocognitive deficit.

One limitation of our investigation is that it was a systemic review, and thus there was substantial heterogeneity in the methods and designs of the studies included in the analysis. Among the different series, there was variability in multiple aspects of the study design, including type of anesthetic, patient inclusion criteria, type of surgery, type of intraoperative cerebral perfusion monitoring, and type of neurocognitive testing. As a result, comparing the groups was difficult, and the generalizability of our findings may be limited. In addition, it is difficult to accurately establish incidence and comprehensively review these events because of the paucity of literature.

Conclusion

Neurocognitive complications after shoulder arthroscopy with the patient in the BCP are extremely rare but potentially devastating events that can affect healthy patients with no preexisting cerebrovascular risk factors. Our review indicated the incidence of permanent neurologic deficit after arthroscopy in the BCP may be as low as 0.004%. The exact etiology of such complications is not clear. Basic science research and large prospective studies are needed to identify the clinically relevant thresholds of magnitude, duration, and frequency of intraoperative CDEs in order to establish their relationship with postoperative neurocognitive complications. Such large studies may also elucidate modifiable patient-specific risk factors and establish the most sensitive, safe, and cost-effective intraoperative monitoring tools. Current literature suggests that accurate intraoperative monitoring of cerebral perfusion, alternatives to general anesthesia, and prudent use of intraoperative blood pressure control may improve patient safety.

The beach-chair position (BCP) is commonly used for both arthroscopic and open shoulder surgery. This technique positions the shoulder in an anatomical upright position, facilitating shoulder access and visualization.¹ Compared with the lateral decubitus position, the BCP also improves airway access, reduces bleeding, and lessens the risk for brachial plexus injury.²

Despite the advantages of using the BCP, there have been multiple reports of catastrophic neurologic complications, including severe brain damage and death, in relatively healthy patients without any known risk factors.^3-6 The definitive etiology of these complications remains unclear, but it has been hypothesized that BCP use may be an independent risk factor for cerebrovascular ischemia,^1,5-16 as the upright position can cause hypotension leading to increased risk for cerebral hypoperfusion.^7-11,17 Reducing cerebral perfusion pressure below critical thresholds may result in permanent neurologic injury.^4-6,14 Therefore, monitoring of cerebral perfusion and optimization of intraoperative cerebral oxygenation have been recommended to help avoid potential neurologic complications. However, a direct relationship between intraoperative cerebral desaturation events (CDEs) and postoperative neurocognitive deficits has not been definitively established.^1,9-12

To put into perspective the importance of detecting and preventing CDEs and neurologic complications, we can consider the incidence of fatal pulmonary embolism associated with total joint arthroplasty. Although the incidence is very low, about 0.1% to 2.0%, some form of venous thromboembolism prophylaxis is the standard of care for helping prevent this serious complication. Similarly, catastrophic neurologic complications of upright shoulder arthroscopy are very rare, but it is still important to consider measures that help minimize them.

We reviewed the literature for the incidence of postoperative neurocognitive deficits, number of reported neurocognitive complications, and incidence of intraoperative CDEs in patients who underwent arthroscopic shoulder surgery in the BCP.

Methods

Dr. Salazar and Dr. Hazel independently searched the Medline, Cochrane, and Embase databases for case series, prospective studies, and cohort studies that reported neurocognitive complications associated with the BCP and the incidence of intraoperative CDEs. The authors used beach chair, desaturation, near infrared spectroscopy, and shoulder as medical subject headings (MeSH). In addition, bibliographies of retrieved articles were checked for studies that the search terms may have missed. Eighty-one publications were identified and reviewed for possible inclusion.

Next, the same 2 authors reviewed the titles and abstracts for relevance and determined which articles had potential to contribute to the study. Only English-language publications were considered for inclusion. To review the incidence of postoperative neurocognitive deficits, we included only those studies with more than 25 patients, documentation of postoperative complications, and arthroscopic shoulder surgery performed with the patient in the seated, semi-upright, or BCP. Only studies with at least 25 patients were used in order to increase the power and improve the level of evidence. To review reported cases of neurocognitive complications, we included all relevant case reports and case series. To review the incidence of intraoperative CDEs and investigate their relationship with postoperative neurocognitive deficits, we included studies that reported on use of intraoperative cerebral perfusion monitoring. Modalities used in these studies included near infrared spectroscopy, electroencephalography, and invasive blood pressure monitoring calculated at the brain level. Studies were excluded if they did not involve arthroscopic shoulder surgery or were not conducted with human subjects.

Information recorded for each study included general information such as author and publication year, type of study, number of patients enrolled, type of intraoperative monitoring, anesthesia protocol, number of patients with CDEs, and number of patients with neurocognitive complications after surgery.

Results

Our search identified 81 publications for potential inclusion. Our first aim was to identify the overall incidence of reported neurocognitive deficits after arthroscopic shoulder surgery with the patient in the BCP. We identified 10 studies (Table 1) that met the inclusion criteria. Among the 24,701 patients in these 10 studies, there was only 1 reported case of neurocognitive deficit after surgery, in a mixed prospective-retrospective study of 15,014 cases by Rohrbaugh and colleagues.18 The deficit they reported was an ischemic cerebral vascular accident. The 0.0067% incidence in their study demonstrates how rare the complication is. Two large retrospective studies (Ns = 4169 and 5177 patients) found no postoperative neurocognitive complications.^19,20 Only 3 studies performed formal postoperative cognitive testing. Salazar and colleagues²¹ used the Repeatable Battery for the Assessment of Neuropsychological Status before and after surgery, and Gillespie and colleagues⁸ and Lee and colleagues¹⁰ used the Mini–Mental State Examination before and after surgery. Total incidence of reported neurocognitive deficits from our review was 0.004% (1/24,701).

Our second aim was to review all reported cases of neurocognitive complications after arthroscopic shoulder surgery with the patient in the BCP. We identified 4 publications that fit our inclusion criteria (Table 2). Pohl and Cullen6 described 4 cases of ischemic brain injury after arthroscopic shoulder surgery with the patient in the BCP. Age range was 47 to 57 years. Specific intraoperative cerebral monitoring was not used. However, these patients had several episodes of intraoperative hypotension (systolic blood pressures, 80-90 mm Hg), measured with a traditional blood pressure cuff on the arm. In general, these patients had minimal cerebrovascular risk factors and no known preexisting cerebrovascular disease. Drummond and colleagues²² described an ischemic stroke in a 50-year-old man after arthroscopic subacromial decompression and open rotator cuff repair that resulted in unresolved right hemiplegia. Subsequent diagnostic investigation revealed an asymmetry of the circle of Willis resulting in limited flow to the left anterior and middle cerebral artery distributions. Bhatti and Enneking³ reported the case of a 64-year-old man who lost vision in the right eye immediately after arthroscopic rotator cuff repair. His vision improved spontaneously the next morning and continued to improve over the next 6 months—he regained 20/20 vision with some residual optic neuropathy.

Our third aim was to determine the incidence of intraoperative CDEs during arthroscopic shoulder surgery with the patient in the BCP. Incidence of CDEs varied widely among the 7 studies reviewed (Table 3). Minimum incidence of intraoperative CDE was 0% in a cohort of 30 patients,¹ and maximum incidence was 80% in a study of 61 patients,¹² all of whom underwent elective arthroscopic shoulder surgery in the BCP. Although there was wide variability in CDE incidence, the studies were consistent with respect to their definition of a CDE. Most authors used a decrease in regional cerebral tissue oxygen saturation of 20% or more from baseline, or an absolute value up to 55%, to define a CDE. None of the 7 studies reviewed reported a clinically significant adverse neurocognitive event.

Discussion

Of concern, there have been several surveys, case reports, and small case series of previously healthy patients who had no known risk factors, underwent arthroscopic shoulder surgery in the BCP, and developed unanticipated postoperative neurologic complications.^4-6,14 Beach-chair positioning during surgical procedures has been implicated as a contributing factor leading to cerebral hypoperfusion with potential for cerebral ischemia.^1,12,23 These changes in cerebral perfusion pressure are thought to be the major determinant of poor neurologic outcomes. Such reports have exposed the potential need for heightened vigilance, alternative anesthesia techniques, and improved monitoring, though the exact etiology of the central nervous system injuries in this patient population is incompletely understood and is likely multifactorial. Therefore, in this study we wanted to determine the incidence of postoperative neurocognitive deficits and review all reported cases of neurocognitive complications in patients who have undergone arthroscopic shoulder surgery in the BCP. In addition, we wanted to define the incidence of intraoperative CDEs and investigate their relationship with postoperative neurocognitive complications.

According to our review, the incidence of postoperative neurocognitive complications after surgery in the BCP is 0.004% (1/24,701). However, this finding is based only on what has been reported; the true incidence is not known. It is also important to note that the incidence of neurocognitive deficits after many other types of surgery is not known and that surgery itself may be a risk factor for postoperative neurocognitive deficits.²⁴ In their retrospective review of 15,014 patients who underwent arthroscopic shoulder surgery in the BCP at a single institution over an 11-year period, Rohrbaugh and colleagues18 found an overall postoperative complication rate of 0.37% and a 0.0067% incidence of neurocognitive deficits. One patient in the series was given a diagnosis of ischemic stroke on the basis of neurologic deficits that occurred 24 hours after surgery. Yadeau and colleagues²⁰ found no postoperative neurocognitive complications in a mixed prospective-retrospective study of 4169 patients—3000 identified retrospectively, 1169 prospectively—who underwent arthroscopic shoulder surgery in the BCP at an ambulatory surgery center. Pin-on and colleagues¹⁹ reported on a series of 5177 orthopedic and neurosurgical patients who underwent surgery in the BCP. In those who had arthroscopic shoulder surgery, intraoperative systolic blood pressures obtained from an arterial line referenced to heart level decreased a mean (SD) of 14.4% (12.7%), whereas in those whose pressures were obtained from a noninvasive blood pressure cuff referenced to heart level decreased 19.3% (12.6%). However, the authors reported no incidence of postoperative stroke or neurologic deficits.

Although uncommon, perioperative cerebral ischemic accidents are potentially devastating for patients, their families, and the health care professionals involved. These events have tremendous economic, social, professional, and medicolegal implications, with perioperative stroke being particularly morbid. Perioperative stroke has a mortality rate of 60%, versus 15% to 46% for stroke in general.^25,26 In 2005, Pohl and Cullen⁶ published a landmark article on a series of 4 relatively healthy middle-aged patients who were at low risk for stroke but had catastrophic neurocognitive complications (including 1 death) after arthroscopic shoulder surgery in the BCP. Bhatti and Enneking³ described a case of acute postoperative vision loss and ophthalmoplegia attributed to intraoperative hypotension leading to ischemia in a patient who underwent an elective shoulder arthroscopic procedure in the BCP. These reports prompted multiple investigations into the physiologic hemodynamic changes associated with surgery in the BCP and the treatment strategies used to improve patient safety.

In the normal physiologic state, the sympathetic nervous system is activated when a person assumes the seated position. The result is increased systemic vascular resistance and heart rate alterations to maintain cardiac output and mean arterial pressure. In anesthetized patients, this response is blunted by the vasodilatory effects of intravenous and volatile anesthetics. Multiple studies have demonstrated substantial hemodynamic changes in both awake and anesthetized patients during the maneuver from the supine position to the seated position^1,27,28; these changes include diminished cardiac index, stroke volume, and arterial pressure.¹⁷ The data underscore the need for attentiveness and accurate monitoring of cerebral perfusion when the transition is made from the supine position to the BCP, particularly in the early phase of surgery and in high-risk patients.

Knowledge of these hemodynamic changes has led several authors to recommend additional intraoperative monitoring of cerebral perfusion. Monitoring techniques have included use of invasive blood pressure monitoring adjusted to brain level, cerebral oximetry using near infrared spectroscopy, and electroencephalography. However, the clinical relevance of intraoperative CDEs in isolation is not well understood.^1,6,7,23 In addition, cost and availability of additional advanced monitoring likely factor into why it is not more commonly used. For this patient population, the severity, frequency, and duration of desaturation that causes cerebral ischemia and the relationship with postoperative neurocognitive deficits remain undefined.

The incidence of CDEs in patients being monitored with near infrared spectroscopy while undergoing elective arthroscopic shoulder surgery in the BCP varies widely, from 0% to 80% (mean, 41%).^{1,4,7,10,12,21} Magnitude and duration of cerebral ischemia required to produce neurocognitive dysfunction in this patient population remain unidentified as well. In conscious patients, a 20% reduction in frontal lobe oxygenation is associated with clinical manifestations of cerebral hypoperfusion, such as syncope.^15,29 As none of the patients in the studies we reviewed experienced any sort of deficit, we cannot definitively state there is a correlation between CDE occurrence and neurocognitive deficit.

One limitation of our investigation is that it was a systemic review, and thus there was substantial heterogeneity in the methods and designs of the studies included in the analysis. Among the different series, there was variability in multiple aspects of the study design, including type of anesthetic, patient inclusion criteria, type of surgery, type of intraoperative cerebral perfusion monitoring, and type of neurocognitive testing. As a result, comparing the groups was difficult, and the generalizability of our findings may be limited. In addition, it is difficult to accurately establish incidence and comprehensively review these events because of the paucity of literature.

Conclusion

Neurocognitive complications after shoulder arthroscopy with the patient in the BCP are extremely rare but potentially devastating events that can affect healthy patients with no preexisting cerebrovascular risk factors. Our review indicated the incidence of permanent neurologic deficit after arthroscopy in the BCP may be as low as 0.004%. The exact etiology of such complications is not clear. Basic science research and large prospective studies are needed to identify the clinically relevant thresholds of magnitude, duration, and frequency of intraoperative CDEs in order to establish their relationship with postoperative neurocognitive complications. Such large studies may also elucidate modifiable patient-specific risk factors and establish the most sensitive, safe, and cost-effective intraoperative monitoring tools. Current literature suggests that accurate intraoperative monitoring of cerebral perfusion, alternatives to general anesthesia, and prudent use of intraoperative blood pressure control may improve patient safety.

A retrospective analysis of children who underwent pulmonary vein stenosis repair with preoperative computed tomography and magnetic resonance imaging from 1990 to 2012 showed that smaller upstream or downstream total cross-sectional area indexed (TCSAi) for body surface area led to poorer survival.

The study of 31 patients at a single institution also indicated that early survival seemed especially poor for patients with a greater number of stenotic veins and upstream pulmonary vein (PV) involvement. The study was published in the March issue of the Journal of Thoracic and Cardiovascular Surgery.

Dr. Mauro Lo Rito and his colleagues at The Hospital for Sick Children, Toronto, retrospectively assessed the 31 patients out of 145 who underwent surgical repair who had had preoperative CT and MRI imaging. Complete sutureless repair was done in 18 (58%), single-side sutureless repair in 12 (39%), and pericardial patch reconstruction in 1 (3%). The mean follow-up was 4.3 years; the median patient age at time of operation was 226 days. Stenosis was bilateral in 45% of patients and unilateral in 55 (J Thorac Cardiovasc Surg. 2016;151:657-66).

In-hospital mortality was 9.7%, with an overall survival of 75%, 69%, and 64% at 1, 3, and 5 years, respectively. Univariate analysis showed that a younger age at operation, lower body surface area, smaller upstream TCSAi, and greater number of PV with stenosis/occlusion were associated with an increased risk of death.

Multivariate analysis showed that smaller upstream TCSAi for body surface area (P = .030) and greater number of stenotic PVs (P = .007) were associated with poor early (less than 1 year) survival. There was a nonsignificant tendency for smaller downstream TCSAi to be associated with poor late survival (greater than 1 year). None of the different PV morphologies were found to influence survival, according to Dr. Lo Rito and his colleagues.

Among the 28 hospital survivors, restenosis occurred in 10 patients, 7 of whom did not undergo further surgery (3 of these were alive at last follow-up and 4 died secondary to disease progression). Of the 3 patients who underwent subsequent intervention, 2 were alive at last follow-up.

“Risk stratification for patients with PV stenosis is currently challenging because of the variability in the anatomic configuration and the unknown relationship between these anatomic variants and survival. Our study demonstrates that by using cross-sectional areas, pulmonary vein cross-sectional area indexed to body surface area (PVCSAi) and TCSAi and tabulating the number of stenotic PVs, we can identify high-risk subsets of patients with high predicted mortality.” Dr. Lo Rito and his colleagues stated.

“The upstream total cross-sectional area and the number of stenotic PVs influence early survival and can be used to guide counseling. Smaller downstream cross-sectional area influences late survival, and those patients should be monitored with close follow-up. This methodology could aid in risk stratification for future clinical trials of pharmacologic agents designed to target upstream pulmonary vasculopathy,” the investigators concluded.

The authors reported that they had no conflicts of interest.

A webcast of the original presentation of these results at the 95th American Association for Thoracic Surgery Annual Meeting is available online (http://webcast.aats.org/2015/Video/Tuesday/04-28-15_6A_1615_Lo_Rito.mp4).

[email protected]

A retrospective analysis of children who underwent pulmonary vein stenosis repair with preoperative computed tomography and magnetic resonance imaging from 1990 to 2012 showed that smaller upstream or downstream total cross-sectional area indexed (TCSAi) for body surface area led to poorer survival.

The study of 31 patients at a single institution also indicated that early survival seemed especially poor for patients with a greater number of stenotic veins and upstream pulmonary vein (PV) involvement. The study was published in the March issue of the Journal of Thoracic and Cardiovascular Surgery.

Dr. Mauro Lo Rito and his colleagues at The Hospital for Sick Children, Toronto, retrospectively assessed the 31 patients out of 145 who underwent surgical repair who had had preoperative CT and MRI imaging. Complete sutureless repair was done in 18 (58%), single-side sutureless repair in 12 (39%), and pericardial patch reconstruction in 1 (3%). The mean follow-up was 4.3 years; the median patient age at time of operation was 226 days. Stenosis was bilateral in 45% of patients and unilateral in 55 (J Thorac Cardiovasc Surg. 2016;151:657-66).

In-hospital mortality was 9.7%, with an overall survival of 75%, 69%, and 64% at 1, 3, and 5 years, respectively. Univariate analysis showed that a younger age at operation, lower body surface area, smaller upstream TCSAi, and greater number of PV with stenosis/occlusion were associated with an increased risk of death.

Multivariate analysis showed that smaller upstream TCSAi for body surface area (P = .030) and greater number of stenotic PVs (P = .007) were associated with poor early (less than 1 year) survival. There was a nonsignificant tendency for smaller downstream TCSAi to be associated with poor late survival (greater than 1 year). None of the different PV morphologies were found to influence survival, according to Dr. Lo Rito and his colleagues.

Among the 28 hospital survivors, restenosis occurred in 10 patients, 7 of whom did not undergo further surgery (3 of these were alive at last follow-up and 4 died secondary to disease progression). Of the 3 patients who underwent subsequent intervention, 2 were alive at last follow-up.

“Risk stratification for patients with PV stenosis is currently challenging because of the variability in the anatomic configuration and the unknown relationship between these anatomic variants and survival. Our study demonstrates that by using cross-sectional areas, pulmonary vein cross-sectional area indexed to body surface area (PVCSAi) and TCSAi and tabulating the number of stenotic PVs, we can identify high-risk subsets of patients with high predicted mortality.” Dr. Lo Rito and his colleagues stated.

“The upstream total cross-sectional area and the number of stenotic PVs influence early survival and can be used to guide counseling. Smaller downstream cross-sectional area influences late survival, and those patients should be monitored with close follow-up. This methodology could aid in risk stratification for future clinical trials of pharmacologic agents designed to target upstream pulmonary vasculopathy,” the investigators concluded.

The authors reported that they had no conflicts of interest.

A webcast of the original presentation of these results at the 95th American Association for Thoracic Surgery Annual Meeting is available online (http://webcast.aats.org/2015/Video/Tuesday/04-28-15_6A_1615_Lo_Rito.mp4).

[email protected]

A retrospective analysis of children who underwent pulmonary vein stenosis repair with preoperative computed tomography and magnetic resonance imaging from 1990 to 2012 showed that smaller upstream or downstream total cross-sectional area indexed (TCSAi) for body surface area led to poorer survival.

The study of 31 patients at a single institution also indicated that early survival seemed especially poor for patients with a greater number of stenotic veins and upstream pulmonary vein (PV) involvement. The study was published in the March issue of the Journal of Thoracic and Cardiovascular Surgery.

Dr. Mauro Lo Rito and his colleagues at The Hospital for Sick Children, Toronto, retrospectively assessed the 31 patients out of 145 who underwent surgical repair who had had preoperative CT and MRI imaging. Complete sutureless repair was done in 18 (58%), single-side sutureless repair in 12 (39%), and pericardial patch reconstruction in 1 (3%). The mean follow-up was 4.3 years; the median patient age at time of operation was 226 days. Stenosis was bilateral in 45% of patients and unilateral in 55 (J Thorac Cardiovasc Surg. 2016;151:657-66).

In-hospital mortality was 9.7%, with an overall survival of 75%, 69%, and 64% at 1, 3, and 5 years, respectively. Univariate analysis showed that a younger age at operation, lower body surface area, smaller upstream TCSAi, and greater number of PV with stenosis/occlusion were associated with an increased risk of death.

Multivariate analysis showed that smaller upstream TCSAi for body surface area (P = .030) and greater number of stenotic PVs (P = .007) were associated with poor early (less than 1 year) survival. There was a nonsignificant tendency for smaller downstream TCSAi to be associated with poor late survival (greater than 1 year). None of the different PV morphologies were found to influence survival, according to Dr. Lo Rito and his colleagues.

Among the 28 hospital survivors, restenosis occurred in 10 patients, 7 of whom did not undergo further surgery (3 of these were alive at last follow-up and 4 died secondary to disease progression). Of the 3 patients who underwent subsequent intervention, 2 were alive at last follow-up.

“Risk stratification for patients with PV stenosis is currently challenging because of the variability in the anatomic configuration and the unknown relationship between these anatomic variants and survival. Our study demonstrates that by using cross-sectional areas, pulmonary vein cross-sectional area indexed to body surface area (PVCSAi) and TCSAi and tabulating the number of stenotic PVs, we can identify high-risk subsets of patients with high predicted mortality.” Dr. Lo Rito and his colleagues stated.

“The upstream total cross-sectional area and the number of stenotic PVs influence early survival and can be used to guide counseling. Smaller downstream cross-sectional area influences late survival, and those patients should be monitored with close follow-up. This methodology could aid in risk stratification for future clinical trials of pharmacologic agents designed to target upstream pulmonary vasculopathy,” the investigators concluded.

The authors reported that they had no conflicts of interest.

A webcast of the original presentation of these results at the 95th American Association for Thoracic Surgery Annual Meeting is available online (http://webcast.aats.org/2015/Video/Tuesday/04-28-15_6A_1615_Lo_Rito.mp4).

[email protected]

LOS ANGELES – The equipoise between carotid stenting and endarterectomy received a further boost in 10-year results from the landmark Carotid Revascularization Endarterectomy versus Stenting Trial (CREST) that compared the two options head-to-head.

Reported the day after results from another big trial that pitted carotid stenting against surgery, the Asymptomatic Carotid Trial (ACT I), the new long-term results from the CREST study mean that deciding among the options relies largely on patient preference although individual clinical characteristics might favor one approach or the other, experts said.

Mitchel L. Zoler/Frontline Medical News

The big remaining unknown and wild card is whether doing no procedural intervention at all and relying entirely on optimal, contemporary medical treatment works just as well as endarterectomy or carotid stenting. The role for stand-alone medical therapy against carotid surgery or stenting (on top of medical therapy) is currently undergoing a formal, direct comparison in the randomized Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial (CREST-2).

Taking the 5-year outcome results from ACT I and the 10-year outcome results from CREST both into account, “we now have a lot of evidence that both carotid stenting and surgery are safe and durable. The results support both options” for either patients with symptomatic carotid artery stenosis or asymptomatic patients with carotid stenosis as extensive as in the patients enrolled in these trials, said Dr. Thomas G. Brott at the International Stroke Conference.

“In routine practice, we lay out the options of endarterectomy, carotid stenting, or no intervention with just medical treatment to patients and let them decide,” noted Dr. Brott, professor of neurology and director of research at the Mayo Clinic in Jacksonville, Fla.

CREST randomized 2,502 symptomatic or asymptomatic patients with significant carotid stenosis during 2000-2008 at 117 U.S. and Canadian centers. From this group, 1,607 consented and were available for long-term follow-up, done at a median of 7.4 years and as long as 10 years after follow-up.

The study’s primary, long-term endpoint was stroke, MI, or death during the periprocedural period (30 days after treatment or 36 days after enrollment depending on when the procedural intervention occurred) plus the rate of ipsilateral stroke during up to 10 years of follow-up. This combined endpoint occurred in 10% of the patients who underwent endarterectomy and in 12% of those who had stenting, a difference that was not statistically significant, Dr. Brott reported. Concurrent with his presentation at the meeting, sponsored by the American Heart Association, the results also were published online (N Engl J Med. 2016 Feb 18. doi: 10.1056/NEJMoa1505215).

The results included a secondary endpoint that showed a significant benefit for endarterectomy. The tally of periprocedural strokes or deaths plus ipsilateral strokes during 10-year follow-up was 8% for the surgical group and 11% for those who received a stent, a 37% excess hazard with stenting.

Dr. Brott attributed this secondary difference between the two arms of the study to a statistically significant excess of stroke or death during the periprocedural period in the patients treated by stenting, and more specifically an excess of strokes. The rate of total periprocedural strokes was 4% with stenting and 2% with endarterectomy, a statistically significant difference. Although an embolic protection device was used “when feasible” during stenting, this protection can be fallible, Dr. Brott noted. In contrast, the results from the ACT I trial showed no statistically significant difference in the rate of periprocedural total strokes between the stented and endarterectomy patients.

Dr. Brott had no relevant disclosures. The CREST trial received partial funding from Abbott Vascular.

[email protected]

On Twitter @mitchelzoler

LOS ANGELES – The equipoise between carotid stenting and endarterectomy received a further boost in 10-year results from the landmark Carotid Revascularization Endarterectomy versus Stenting Trial (CREST) that compared the two options head-to-head.

Reported the day after results from another big trial that pitted carotid stenting against surgery, the Asymptomatic Carotid Trial (ACT I), the new long-term results from the CREST study mean that deciding among the options relies largely on patient preference although individual clinical characteristics might favor one approach or the other, experts said.

Mitchel L. Zoler/Frontline Medical News

The big remaining unknown and wild card is whether doing no procedural intervention at all and relying entirely on optimal, contemporary medical treatment works just as well as endarterectomy or carotid stenting. The role for stand-alone medical therapy against carotid surgery or stenting (on top of medical therapy) is currently undergoing a formal, direct comparison in the randomized Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial (CREST-2).

Taking the 5-year outcome results from ACT I and the 10-year outcome results from CREST both into account, “we now have a lot of evidence that both carotid stenting and surgery are safe and durable. The results support both options” for either patients with symptomatic carotid artery stenosis or asymptomatic patients with carotid stenosis as extensive as in the patients enrolled in these trials, said Dr. Thomas G. Brott at the International Stroke Conference.

“In routine practice, we lay out the options of endarterectomy, carotid stenting, or no intervention with just medical treatment to patients and let them decide,” noted Dr. Brott, professor of neurology and director of research at the Mayo Clinic in Jacksonville, Fla.

CREST randomized 2,502 symptomatic or asymptomatic patients with significant carotid stenosis during 2000-2008 at 117 U.S. and Canadian centers. From this group, 1,607 consented and were available for long-term follow-up, done at a median of 7.4 years and as long as 10 years after follow-up.

The study’s primary, long-term endpoint was stroke, MI, or death during the periprocedural period (30 days after treatment or 36 days after enrollment depending on when the procedural intervention occurred) plus the rate of ipsilateral stroke during up to 10 years of follow-up. This combined endpoint occurred in 10% of the patients who underwent endarterectomy and in 12% of those who had stenting, a difference that was not statistically significant, Dr. Brott reported. Concurrent with his presentation at the meeting, sponsored by the American Heart Association, the results also were published online (N Engl J Med. 2016 Feb 18. doi: 10.1056/NEJMoa1505215).

The results included a secondary endpoint that showed a significant benefit for endarterectomy. The tally of periprocedural strokes or deaths plus ipsilateral strokes during 10-year follow-up was 8% for the surgical group and 11% for those who received a stent, a 37% excess hazard with stenting.

Dr. Brott attributed this secondary difference between the two arms of the study to a statistically significant excess of stroke or death during the periprocedural period in the patients treated by stenting, and more specifically an excess of strokes. The rate of total periprocedural strokes was 4% with stenting and 2% with endarterectomy, a statistically significant difference. Although an embolic protection device was used “when feasible” during stenting, this protection can be fallible, Dr. Brott noted. In contrast, the results from the ACT I trial showed no statistically significant difference in the rate of periprocedural total strokes between the stented and endarterectomy patients.

Dr. Brott had no relevant disclosures. The CREST trial received partial funding from Abbott Vascular.

[email protected]

On Twitter @mitchelzoler

LOS ANGELES – The equipoise between carotid stenting and endarterectomy received a further boost in 10-year results from the landmark Carotid Revascularization Endarterectomy versus Stenting Trial (CREST) that compared the two options head-to-head.

Reported the day after results from another big trial that pitted carotid stenting against surgery, the Asymptomatic Carotid Trial (ACT I), the new long-term results from the CREST study mean that deciding among the options relies largely on patient preference although individual clinical characteristics might favor one approach or the other, experts said.

Mitchel L. Zoler/Frontline Medical News

The big remaining unknown and wild card is whether doing no procedural intervention at all and relying entirely on optimal, contemporary medical treatment works just as well as endarterectomy or carotid stenting. The role for stand-alone medical therapy against carotid surgery or stenting (on top of medical therapy) is currently undergoing a formal, direct comparison in the randomized Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial (CREST-2).

Taking the 5-year outcome results from ACT I and the 10-year outcome results from CREST both into account, “we now have a lot of evidence that both carotid stenting and surgery are safe and durable. The results support both options” for either patients with symptomatic carotid artery stenosis or asymptomatic patients with carotid stenosis as extensive as in the patients enrolled in these trials, said Dr. Thomas G. Brott at the International Stroke Conference.

“In routine practice, we lay out the options of endarterectomy, carotid stenting, or no intervention with just medical treatment to patients and let them decide,” noted Dr. Brott, professor of neurology and director of research at the Mayo Clinic in Jacksonville, Fla.

CREST randomized 2,502 symptomatic or asymptomatic patients with significant carotid stenosis during 2000-2008 at 117 U.S. and Canadian centers. From this group, 1,607 consented and were available for long-term follow-up, done at a median of 7.4 years and as long as 10 years after follow-up.

The study’s primary, long-term endpoint was stroke, MI, or death during the periprocedural period (30 days after treatment or 36 days after enrollment depending on when the procedural intervention occurred) plus the rate of ipsilateral stroke during up to 10 years of follow-up. This combined endpoint occurred in 10% of the patients who underwent endarterectomy and in 12% of those who had stenting, a difference that was not statistically significant, Dr. Brott reported. Concurrent with his presentation at the meeting, sponsored by the American Heart Association, the results also were published online (N Engl J Med. 2016 Feb 18. doi: 10.1056/NEJMoa1505215).

The results included a secondary endpoint that showed a significant benefit for endarterectomy. The tally of periprocedural strokes or deaths plus ipsilateral strokes during 10-year follow-up was 8% for the surgical group and 11% for those who received a stent, a 37% excess hazard with stenting.

Dr. Brott attributed this secondary difference between the two arms of the study to a statistically significant excess of stroke or death during the periprocedural period in the patients treated by stenting, and more specifically an excess of strokes. The rate of total periprocedural strokes was 4% with stenting and 2% with endarterectomy, a statistically significant difference. Although an embolic protection device was used “when feasible” during stenting, this protection can be fallible, Dr. Brott noted. In contrast, the results from the ACT I trial showed no statistically significant difference in the rate of periprocedural total strokes between the stented and endarterectomy patients.

Dr. Brott had no relevant disclosures. The CREST trial received partial funding from Abbott Vascular.

[email protected]

On Twitter @mitchelzoler

To improve patient care and outcomes, leading dermatologists offered their recommendations on facial sunscreens. Consideration must be given to:

• Anthelios SX
  La Roche-Posay Laboratoire Dermatologique
  "This medium-weight facial moisturizing cream with broad-spectrum sunscreen seems to be a widely accepted option for daily patient use, and I use it myself.”
  —Lorraine L. Rosamilia, MD, State College, Pennsylvania

• Anthelios 50
  La Roche-Posay Laboratoire Dermatologique
  Recommended by Gary Goldenberg, MD, New York, New York

• Elizabeth Arden Pro Triple Protection Factor SPF 50
  Elizabeth Arden, Inc.
  “This is a tinted, chemical-free SPF 50 sunscreen that looks, feels, and smells like its made by a cosmetic company that understands what people want in a skin care product. Additionally, it has several antioxidants and DNA repair enzyme. So not only is it protecting the skin from UV damage, but it’s trying to reverse some of that damage as well.”
  —Mark G. Rubin, MD, Beverly Hills, California

• EltaMD UV Clear Broad-Spectrum SPF 46
  EltaMD
  “This sunscreen has an elegant feel upon application and leaves little residue, making it a nice product for daily facial application.”
  —Neil Fernandes, MD, Phoenix, Arizona

• Neutrogena Age Shield Face Lotion Sunscreen
  Johnson & Johnson Consumer Inc
  “This sunscreen has broad UV spectrum coverage that blocks against harmful UVA and UVB rays. It has the added benefit of having antioxidants that may slow and reverse photoaging.”
  —Shari Lipner, MD, PhD, New York, New York

• Sheer Physical UV Defense SPF 50
  SkinCeuticals
  “It is very lightweight, especially for a physical block, and is noncomedogenic and sheer but still provides broad-spectrum coverage with both titanium dioxide and zinc oxide. There is a tinted version as well that I often recommend for women.”
  —Monica Schadlow, MD, New York, New York

Cutis invites readers to send us their recommendations. Hand creams, scar treatments, and body scrubs will be featured in upcoming editions of Cosmetic Corner. Please e-mail your recommendation(s) to the Editorial Office.

Disclaimer: Opinions expressed herein do not necessarily reflect those of Cutis or Frontline Medical Communications Inc. and shall not be used for product endorsement purposes. Any reference made to a specific commercial product does not indicate or imply that Cutis or Frontline Medical Communications Inc. endorses, recommends, or favors the product mentioned. No guarantee is given to the effects of recommended products.

To improve patient care and outcomes, leading dermatologists offered their recommendations on facial sunscreens. Consideration must be given to:

• Anthelios SX
  La Roche-Posay Laboratoire Dermatologique
  "This medium-weight facial moisturizing cream with broad-spectrum sunscreen seems to be a widely accepted option for daily patient use, and I use it myself.”
  —Lorraine L. Rosamilia, MD, State College, Pennsylvania

• Anthelios 50
  La Roche-Posay Laboratoire Dermatologique
  Recommended by Gary Goldenberg, MD, New York, New York

• Elizabeth Arden Pro Triple Protection Factor SPF 50
  Elizabeth Arden, Inc.
  “This is a tinted, chemical-free SPF 50 sunscreen that looks, feels, and smells like its made by a cosmetic company that understands what people want in a skin care product. Additionally, it has several antioxidants and DNA repair enzyme. So not only is it protecting the skin from UV damage, but it’s trying to reverse some of that damage as well.”
  —Mark G. Rubin, MD, Beverly Hills, California

• EltaMD UV Clear Broad-Spectrum SPF 46
  EltaMD
  “This sunscreen has an elegant feel upon application and leaves little residue, making it a nice product for daily facial application.”
  —Neil Fernandes, MD, Phoenix, Arizona

• Neutrogena Age Shield Face Lotion Sunscreen
  Johnson & Johnson Consumer Inc
  “This sunscreen has broad UV spectrum coverage that blocks against harmful UVA and UVB rays. It has the added benefit of having antioxidants that may slow and reverse photoaging.”
  —Shari Lipner, MD, PhD, New York, New York

• Sheer Physical UV Defense SPF 50
  SkinCeuticals
  “It is very lightweight, especially for a physical block, and is noncomedogenic and sheer but still provides broad-spectrum coverage with both titanium dioxide and zinc oxide. There is a tinted version as well that I often recommend for women.”
  —Monica Schadlow, MD, New York, New York

Cutis invites readers to send us their recommendations. Hand creams, scar treatments, and body scrubs will be featured in upcoming editions of Cosmetic Corner. Please e-mail your recommendation(s) to the Editorial Office.

Disclaimer: Opinions expressed herein do not necessarily reflect those of Cutis or Frontline Medical Communications Inc. and shall not be used for product endorsement purposes. Any reference made to a specific commercial product does not indicate or imply that Cutis or Frontline Medical Communications Inc. endorses, recommends, or favors the product mentioned. No guarantee is given to the effects of recommended products.

To improve patient care and outcomes, leading dermatologists offered their recommendations on facial sunscreens. Consideration must be given to:

• Anthelios SX
  La Roche-Posay Laboratoire Dermatologique
  "This medium-weight facial moisturizing cream with broad-spectrum sunscreen seems to be a widely accepted option for daily patient use, and I use it myself.”
  —Lorraine L. Rosamilia, MD, State College, Pennsylvania

• Anthelios 50
  La Roche-Posay Laboratoire Dermatologique
  Recommended by Gary Goldenberg, MD, New York, New York

• Elizabeth Arden Pro Triple Protection Factor SPF 50
  Elizabeth Arden, Inc.
  “This is a tinted, chemical-free SPF 50 sunscreen that looks, feels, and smells like its made by a cosmetic company that understands what people want in a skin care product. Additionally, it has several antioxidants and DNA repair enzyme. So not only is it protecting the skin from UV damage, but it’s trying to reverse some of that damage as well.”
  —Mark G. Rubin, MD, Beverly Hills, California

• EltaMD UV Clear Broad-Spectrum SPF 46
  EltaMD
  “This sunscreen has an elegant feel upon application and leaves little residue, making it a nice product for daily facial application.”
  —Neil Fernandes, MD, Phoenix, Arizona

• Neutrogena Age Shield Face Lotion Sunscreen
  Johnson & Johnson Consumer Inc
  “This sunscreen has broad UV spectrum coverage that blocks against harmful UVA and UVB rays. It has the added benefit of having antioxidants that may slow and reverse photoaging.”
  —Shari Lipner, MD, PhD, New York, New York

• Sheer Physical UV Defense SPF 50
  SkinCeuticals
  “It is very lightweight, especially for a physical block, and is noncomedogenic and sheer but still provides broad-spectrum coverage with both titanium dioxide and zinc oxide. There is a tinted version as well that I often recommend for women.”
  —Monica Schadlow, MD, New York, New York

Cutis invites readers to send us their recommendations. Hand creams, scar treatments, and body scrubs will be featured in upcoming editions of Cosmetic Corner. Please e-mail your recommendation(s) to the Editorial Office.

Disclaimer: Opinions expressed herein do not necessarily reflect those of Cutis or Frontline Medical Communications Inc. and shall not be used for product endorsement purposes. Any reference made to a specific commercial product does not indicate or imply that Cutis or Frontline Medical Communications Inc. endorses, recommends, or favors the product mentioned. No guarantee is given to the effects of recommended products.

Injuries among professional baseball players have been on the rise for several years.^1,2 From 1989 to 1999, the number of disabled list (DL) reports increased 38% (266 to 367 annual reports),¹ and a similar increase in injury rates was noted from the 2002 to the 2008 seasons (37%).² These injuries have important implications for future injury risk and time away from play. Identifying these injuries and determining correlates and risk factors is important for targeted prevention efforts.

Several studies have explored the prevalence of upper extremity injuries in professional and collegiate baseball players;^2-4 however, detailed epidemiology of knee injuries in Major League Baseball (MLB) and Minor League Baseball (MiLB) players is lacking. Much more is known about the prevalence, treatment, and outcomes of knee injuries in other professional sporting organizations, such as the National Basketball Association (NBA), National Football League (NFL), and National Hockey League (NHL).^4-12 A recent meta-analysis exploring injuries in professional athletes found that studies on lower extremity injuries comprised approximately 12% of the literature reporting injuries in MLB players.⁴ In other professional leagues, publications on lower extremity injuries comprise approximately 56% of the sports medicine literature in the NFL, 54% in the NBA, and 62% in the NHL.⁴ Since few studies have investigated lower extremity injuries among professional baseball players, there is an opportunity for additional research to guide evidence-based prevention strategies.

A better understanding of the nature of these injuries is one of the first steps towards developing targeted injury prevention programs and treatment algorithms. The study of injury epidemiology among professional baseball players has been aided by the creation of an injury tracking system initiated by the MLB, its minor league affiliates, and the Major League Baseball Players Association.^5,13,14 This surveillance system allows for the tracking of medical histories and injuries to players as they move across major and minor league organizations. Similar systems have been utilized in the National Collegiate Athletic Association and other professional sports organizations.^3,15-17 A unique advantage of the MLB surveillance system is the required participation of all major and minor league teams, which allows for investigation of the entire population of players rather than simply a sample of players from select teams. This system has propelled an effort to identify injury patterns as a means of developing appropriate targets for potential preventative measures.⁵

The purpose of this descriptive epidemiologic study is to better understand the distribution and characteristics of knee injuries in these elite athletes by reporting on all knee injuries occurring over a span of 4 seasons (2011-2014). Additionally, this study seeks to characterize the impact of these injuries by analyzing the time required for return to play and the treatments rendered (surgical and nonsurgical).

Materials and Methods

After approval from the Johns Hopkins Bloomberg School of Public Health Institutional Review Board, detailed data regarding knee injuries in both MLB and MiLB baseball players were extracted from the de-identified MLB Health and Injury Tracking System (HITS). The HITS database is a centralized database that contains data on injuries from an electronic medical record (EMR). All players provided consent to have their data included in this EMR. HITS system captures injuries reported by the athletic trainers for all professional baseball players from 30 MLB clubs and their 230 minor league affiliates. Additional details on this population of professional baseball players have been published elsewhere.⁵ Only injuries that result in time out of play (≥1 day missed) are included in the database, and they are logged with basic information such as region of the body, diagnosis, date, player position, activity leading to injury, and general treatment. Any injury that affects participation in any aspect of baseball-related activity (eg, game, practice, warm-up, conditioning, weight training) is captured in HITS.

All baseball-related knee injuries occurring during the 2011-2014 seasons that resulted in time out of sport were included in the study. These injuries were identified based on the Sports Medicine Diagnostic Coding System (SMDCS) to capture injuries by diagnostic groups.¹⁸ Knee injuries were included if they occurred during spring training, regular season, or postseason play. Offseason injuries were not included. Injury events that were classified as “season-ending” were not included in the analysis of days missed because many of these players may not have been cleared to play until the beginning of the following season. To determine the proportion of knee injuries during the study period, all injuries were included for comparative purposes (subdivided based on 30 anatomic regions or types).

For each knee injury, a number of variables were analyzed, including diagnosis, level of play (MLB vs. MiLB), age, player position at the time of injury (pitcher, catcher, infield, outfield, base runner, or batter), field location where the injury occurred (home plate, pitcher’s mound, infield, outfield, foul territory or bullpen, or other), mechanism of injury, days missed, and treatment rendered (conservative vs surgical). The classification used to describe the mechanism of injury consisted of contact with ball, contact with ground, contact with another player, contact with another object, or noncontact.

Statistical Analysis
Epidemiologic data are presented with descriptive statistics such as mean, median, frequency, and percentage where appropriate. When comparing player age, days missed, and surgical vs nonsurgical treatment between MLB and MiLB players, t-tests and tests for difference in proportions were applied as appropriate. Statistical significance was established for P values < .05.

The distribution of days missed for the variables considered was often skewed to the right (ie, days missed mostly concentrated on the low to moderate number of days, with fewer values in the much higher days missed range), even after excluding the season-ending injuries; hence the mean (or average) days missed was often larger than the median days missed. Reporting the median would allow for a robust estimate of the expected number of days missed, but would down weight those instances when knee injuries result in much longer missed days, as reflected by the mean. Because of the importance of the days missed measure for professional baseball, both the mean and median are presented.

In order to estimate exposure, the average number of players per team per game was calculated based on analysis of regular season game participation via box scores. This average number over a season, multiplied by the number of team games at each professional level of baseball, was used as an estimate of athlete exposures in order to provide rates comparable to those of other injury surveillance systems. Injury rates were reported as injuries per 1000 athlete-exposures (AE) for those knee injuries that occurred during the regular season. It should be noted that the number of regular season knee injuries and the subsequent AE rates are based on injuries that were deemed work-related during the regular season. This does not necessarily only include injuries occurring during the course of a game, but injuries in game preparation as well. Due to the variations in spring training games and fluctuating rosters, an exposure rate could not be calculated for spring training knee injuries.

RESULTS

Overall Summary

Of the 30 general body regions/systems included in the HITS database, injuries to the knee were the fifth most common reason for days missed in all of professional baseball from 2011-2014 (Table 1). Injuries to the knee represented 6.5% of the nearly 34,000 injuries sustained during the study period. Knee injuries were the fifth most common reason for time out of play for players in both the MiLB and MLB.

A total of 2171 isolated knee injuries resulted in time out of sport for professional baseball players (Table 2). Of these, 410 (19%) occurred in MLB players and 1761 (81%) occurred in MiLB players. MLB players were older than MiLB players at the time of injury (29.5 vs 22.8 years, respectively). Overall mean number of days missed was 16.2 days per knee injury, with MLB players missing an approximately 7 days more per injury than MiLB athletes (21.8 vs. 14.9 days respectively; P = .001).Over the course of the 4 seasons, a total of 30,449 days were missed due to knee injuries in professional baseball, giving an average rate of 7612 days lost per season. Surgery was performed for 263 (12.1%) of the 2171 knee injuries, with a greater proportion of MLB players requiring surgery than MiLB players (17.3% vs 10.9%) (P < .001). With respect to number of days missed per injury, 26% of knee injuries in the minor leagues resulted in greater than 30 days missed, while this number rose to 32% for knee injuries in MLB players (Table 3).

For regular season games, it was estimated that there were 1,197,738 MiLB and 276,608 MLB AE, respectively, over the course of the 4 seasons (2011-2014). The overall knee injury rate across both the MiLB and MLB was 1.2 per 1000 AE, based on the subset of 308 and 1473 regular season knee injuries in MiLB and MLB, respectively. The rate of knee injury was similar and not significantly different between the MiLB and MLB (1.2 per 1000 AE in the MiLB and 1.1 per 1000 AE in the MLB).

Characteristics of Injuries

When considering the position of the player during injury, defensive players were most frequently injured (n = 742, 56.5%), with pitchers (n = 227, 17.3%), infielders (n =193, 14.7%), outfielders (n = 193, 14.7%), and catchers (n = 129, 9.8%) sustaining injuries in decreasing frequency. Injuries while on offense (n = 571, 43.5%) were most frequent in base runners (n = 320, 24.4%) followed by batters (n = 251, 19.1%) (Table 4). Injuries while on defense occurring in infielders and catchers resulted in the longest period of time away from play (average of 22.4 and 20.8 days missed, respectively), while those occurring in batters resulted in the least average days missed (8.9 days).

The most common field location for knee injuries to occur was the infield, which was responsible for n = 647 (29.8%) of the total knee injuries (Table 4). This was followed by home plate (n = 493, 22.7%), other locations outside those specified (n = 394, 18.1%), outfield (n = 320, 14.7%), pitcher’s mound (n = 210, 9.7%), and foul territory or the bullpen (n = 107, 4.9%). Of the knee injuries with a specified location, those occurring in foul territory or the bullpen resulted in the highest mean days missed (18.4), while those occurring at home plate resulted in the least mean days missed (13.4 days).

When analyzed by mechanism of injury, noncontact injuries (n = 953, 43.9%) were more common than being hit with the ball (n = 374, 17.2%), striking the ground (n = 409, 18.8%), other mechanisms not listed (n = 196, 9%), contact with another player (n = 176, 8.1%), or contact with other objects (n = 63, 2.9%) (Table 4). Noncontact injuries and player to player collisions resulted in the greatest number of missed days (21.6 and 17.1 days, respectively) while being struck by the ball resulted in the least mean days missed (5.1).

Of the n = 493 knee injuries occurring at home plate, n = 212 (43%) occurred to the batter, n = 100 (20%) to the catcher, n = 34 (6.9%) to base runners, and n = 7 (1.4%) to pitchers (Table 5). The majority of knee injuries in the infield occurred to base runners (n = 283, 43.7%). Player-to-player collisions at home plate were responsible for 51 (2.3%) knee injuries, while 163 (24%) were noncontact injuries and 376 (56%) were the result of a player being hit by the ball (Table 5).

Injury Diagnosis

By diagnosis, the most common knee injuries observed were contusions or hematomas (n = 662, 30.5%), other injuries (n = 415, 19.1%), sprains or ligament injuries (n = 380, 17.5%), tendinopathies or bursitis (n = 367, 16.9%), and meniscal or cartilage injury (n = 200, 9.2%) (Table 6). Injuries resulting in the greatest mean number of days missed included meniscal or cartilage injuries (44 days), sprains or ligament injuries (30 days), or dislocations (22 days).

Based on specific SMDCS descriptors, the most frequent knee injuries reported were contusion (n = 662, 30.5%), patella tendinopathy (n = 222, 10.2%), and meniscal tears (n = 200, 9.2%) (Table 6). Complete anterior cruciate ligament tears, although infrequent, were responsible for the greatest mean days missed (156.2 days). This was followed by lateral meniscus tears (47.5 days) and medial meniscus tears (41.2 days). Knee contusions, although very common, resulted in the least number of days missed (6.0 days).

Discussion

Although much is known about knee injuries in other professional athletic leagues, little is known about knee injuries in professional baseball players.^2-4 The majority of epidemiologic studies regarding baseball players at any level emphasizes the study of shoulder and elbow injuries.^3,4,19 Since the implementation of the electronic medical record and the HITS database in professional baseball, there has been increased effort to document injuries that have received less attention in the existing literature. Understanding the epidemiology of these injuries is important for the development of targeted prevention efforts.

Prior studies of injuries in professional baseball relied on data captured by the publicly available DL. Posner and colleagues² provide one of the most comprehensive reports on MLB injuries in a report utilizing DL assignment data over a period of 7 seasons.They demonstrated that knee injuries were responsible for 7.7% (12.5% for fielders and 3.7% for pitchers) of assignments to the DL. The current study utilized a comprehensive surveillance and builds on this existing knowledge. The present study found similar trends to Posner and colleagues² in that knee injuries were responsible for 6.5% of injuries in professional baseball players that resulted in missed games. From the 2002 season to the 2008 season, knee injuries were the fifth most common reason MLB players were placed on the DL,² and the current study indicates that they remain the fifth most common reason for missed time from play based on the HITS data. Since the prevalence of these injuries have remained constant since the 2002 season, efforts to better understand these injuries are warranted in order to identify strategies to prevent them. These analyses have generated important data towards achieving this understanding.

As with most injuries in professional sports, goals for treatment are aimed at maximizing patient function and performance while minimizing time out of play. For the 2011-2014 professional baseball seasons, a total of 2171 players sustained knee injuries and missed an average of 16.2 days per injury. Knee injuries were responsible for a total of 7612 days of missed work for MLB and MiLB players per season (30,449 days over the 4-season study period). This is equivalent to a total of 20.9 years of players’ time lost in professional baseball per season over the last 4 years. The implications of this amount of time away from sport are significant, and further study should be targeted at prevention of these injuries and optimizing return to play times.

When attempting to reduce the burden of knee injuries in professional baseball, it may prove beneficial to first understand how the injuries occur, where on the field, and who is at greatest risk. From 2011 to 2014, nearly 44% of knee injuries occurred by noncontact mechanisms. Among all locations on the field where knee injuries occurred, those occurring in the infield were responsible for the greatest mean days missed. The players who seem to be at greatest risk for knee injuries appear to be base runners. These data suggest the need for prevention efforts targeting base runners and infield players, as well as players in MiLB, where the largest number of injuries occurred.

Recently, playing rules implemented by MLB after consultation with players have focused on reducing the number of player-to-player collisions at home plate in an attempt to decrease the injury burden to catchers and base runners.²⁰ This present analysis suggests that this rule change may also reduce the occurrence of knee injuries, as player collisions at home plate were responsible for a total of 51 knee injuries during the study period. The impact of this rule change on injury rates should also be explored. Interestingly, of the 51 knees injuries occurring due to contact at home plate, 23 occurred in 2011, and only 2 occurred in 2014—the first year of the new rule. Additional areas that resulted in high numbers of knee injuries were player-to-player contact in the infield and player contact with the ground in the infield.

Attempting to reduce injury burden and time out of play related to knee injuries in professional baseball players will likely prove to be a difficult task. In order to generate meaningful improvement, a comprehensive approach that involves players, management, trainers, therapists, and physicians will likely be required. As the first report of the epidemiology of knee injuries in professional baseball players, this study is one important step in that process. The strengths of this study are its comprehensive nature that analyzes injuries from an entire population of players on more than 200 teams over a 3-year period. Also, this research is strengthened by its focus on one particular region of the body that has received limited attention in the empirical literature, but represents a significant source of lost time during the baseball season.

There are some limitations to this study. As with any injury surveillance system, there is the possibility that not all cases were captured. Additionally, since the surveillance system is based on data from multiple teams, data entry discrepancy is possible; however, the presence of dropdown boxes and systematic definitions for injuries reduces this risk. Finally, this study did not investigate the various treatments for knee injuries beyond whether or not the injury required surgery. Since this was the first comprehensive exploration of knee injuries in professional baseball, future studies are needed to explore additional facets including outcomes related to treatment, return to play, and performance.

Conclusion

Knee injuries represent 6.5% of all injuries in professional baseball, occurring at a rate of 1.3 per 1000 AE. The burden of these injuries is significant for professional baseball players. This study fills a critical gap in sports injury research by contributing to the knowledge about the effect of knee injuries in professional baseball. It also provides an important foundation for future epidemiologic inquiry to identify modifiable risk factors and interventions that may reduce the impact of these injuries in athletes.

Injuries among professional baseball players have been on the rise for several years.^1,2 From 1989 to 1999, the number of disabled list (DL) reports increased 38% (266 to 367 annual reports),¹ and a similar increase in injury rates was noted from the 2002 to the 2008 seasons (37%).² These injuries have important implications for future injury risk and time away from play. Identifying these injuries and determining correlates and risk factors is important for targeted prevention efforts.

Several studies have explored the prevalence of upper extremity injuries in professional and collegiate baseball players;^2-4 however, detailed epidemiology of knee injuries in Major League Baseball (MLB) and Minor League Baseball (MiLB) players is lacking. Much more is known about the prevalence, treatment, and outcomes of knee injuries in other professional sporting organizations, such as the National Basketball Association (NBA), National Football League (NFL), and National Hockey League (NHL).^4-12 A recent meta-analysis exploring injuries in professional athletes found that studies on lower extremity injuries comprised approximately 12% of the literature reporting injuries in MLB players.⁴ In other professional leagues, publications on lower extremity injuries comprise approximately 56% of the sports medicine literature in the NFL, 54% in the NBA, and 62% in the NHL.⁴ Since few studies have investigated lower extremity injuries among professional baseball players, there is an opportunity for additional research to guide evidence-based prevention strategies.

A better understanding of the nature of these injuries is one of the first steps towards developing targeted injury prevention programs and treatment algorithms. The study of injury epidemiology among professional baseball players has been aided by the creation of an injury tracking system initiated by the MLB, its minor league affiliates, and the Major League Baseball Players Association.^5,13,14 This surveillance system allows for the tracking of medical histories and injuries to players as they move across major and minor league organizations. Similar systems have been utilized in the National Collegiate Athletic Association and other professional sports organizations.^3,15-17 A unique advantage of the MLB surveillance system is the required participation of all major and minor league teams, which allows for investigation of the entire population of players rather than simply a sample of players from select teams. This system has propelled an effort to identify injury patterns as a means of developing appropriate targets for potential preventative measures.⁵

The purpose of this descriptive epidemiologic study is to better understand the distribution and characteristics of knee injuries in these elite athletes by reporting on all knee injuries occurring over a span of 4 seasons (2011-2014). Additionally, this study seeks to characterize the impact of these injuries by analyzing the time required for return to play and the treatments rendered (surgical and nonsurgical).

Materials and Methods

After approval from the Johns Hopkins Bloomberg School of Public Health Institutional Review Board, detailed data regarding knee injuries in both MLB and MiLB baseball players were extracted from the de-identified MLB Health and Injury Tracking System (HITS). The HITS database is a centralized database that contains data on injuries from an electronic medical record (EMR). All players provided consent to have their data included in this EMR. HITS system captures injuries reported by the athletic trainers for all professional baseball players from 30 MLB clubs and their 230 minor league affiliates. Additional details on this population of professional baseball players have been published elsewhere.⁵ Only injuries that result in time out of play (≥1 day missed) are included in the database, and they are logged with basic information such as region of the body, diagnosis, date, player position, activity leading to injury, and general treatment. Any injury that affects participation in any aspect of baseball-related activity (eg, game, practice, warm-up, conditioning, weight training) is captured in HITS.

All baseball-related knee injuries occurring during the 2011-2014 seasons that resulted in time out of sport were included in the study. These injuries were identified based on the Sports Medicine Diagnostic Coding System (SMDCS) to capture injuries by diagnostic groups.¹⁸ Knee injuries were included if they occurred during spring training, regular season, or postseason play. Offseason injuries were not included. Injury events that were classified as “season-ending” were not included in the analysis of days missed because many of these players may not have been cleared to play until the beginning of the following season. To determine the proportion of knee injuries during the study period, all injuries were included for comparative purposes (subdivided based on 30 anatomic regions or types).

For each knee injury, a number of variables were analyzed, including diagnosis, level of play (MLB vs. MiLB), age, player position at the time of injury (pitcher, catcher, infield, outfield, base runner, or batter), field location where the injury occurred (home plate, pitcher’s mound, infield, outfield, foul territory or bullpen, or other), mechanism of injury, days missed, and treatment rendered (conservative vs surgical). The classification used to describe the mechanism of injury consisted of contact with ball, contact with ground, contact with another player, contact with another object, or noncontact.

Statistical Analysis
Epidemiologic data are presented with descriptive statistics such as mean, median, frequency, and percentage where appropriate. When comparing player age, days missed, and surgical vs nonsurgical treatment between MLB and MiLB players, t-tests and tests for difference in proportions were applied as appropriate. Statistical significance was established for P values < .05.

The distribution of days missed for the variables considered was often skewed to the right (ie, days missed mostly concentrated on the low to moderate number of days, with fewer values in the much higher days missed range), even after excluding the season-ending injuries; hence the mean (or average) days missed was often larger than the median days missed. Reporting the median would allow for a robust estimate of the expected number of days missed, but would down weight those instances when knee injuries result in much longer missed days, as reflected by the mean. Because of the importance of the days missed measure for professional baseball, both the mean and median are presented.

In order to estimate exposure, the average number of players per team per game was calculated based on analysis of regular season game participation via box scores. This average number over a season, multiplied by the number of team games at each professional level of baseball, was used as an estimate of athlete exposures in order to provide rates comparable to those of other injury surveillance systems. Injury rates were reported as injuries per 1000 athlete-exposures (AE) for those knee injuries that occurred during the regular season. It should be noted that the number of regular season knee injuries and the subsequent AE rates are based on injuries that were deemed work-related during the regular season. This does not necessarily only include injuries occurring during the course of a game, but injuries in game preparation as well. Due to the variations in spring training games and fluctuating rosters, an exposure rate could not be calculated for spring training knee injuries.

RESULTS

Overall Summary

Of the 30 general body regions/systems included in the HITS database, injuries to the knee were the fifth most common reason for days missed in all of professional baseball from 2011-2014 (Table 1). Injuries to the knee represented 6.5% of the nearly 34,000 injuries sustained during the study period. Knee injuries were the fifth most common reason for time out of play for players in both the MiLB and MLB.

A total of 2171 isolated knee injuries resulted in time out of sport for professional baseball players (Table 2). Of these, 410 (19%) occurred in MLB players and 1761 (81%) occurred in MiLB players. MLB players were older than MiLB players at the time of injury (29.5 vs 22.8 years, respectively). Overall mean number of days missed was 16.2 days per knee injury, with MLB players missing an approximately 7 days more per injury than MiLB athletes (21.8 vs. 14.9 days respectively; P = .001).Over the course of the 4 seasons, a total of 30,449 days were missed due to knee injuries in professional baseball, giving an average rate of 7612 days lost per season. Surgery was performed for 263 (12.1%) of the 2171 knee injuries, with a greater proportion of MLB players requiring surgery than MiLB players (17.3% vs 10.9%) (P < .001). With respect to number of days missed per injury, 26% of knee injuries in the minor leagues resulted in greater than 30 days missed, while this number rose to 32% for knee injuries in MLB players (Table 3).

For regular season games, it was estimated that there were 1,197,738 MiLB and 276,608 MLB AE, respectively, over the course of the 4 seasons (2011-2014). The overall knee injury rate across both the MiLB and MLB was 1.2 per 1000 AE, based on the subset of 308 and 1473 regular season knee injuries in MiLB and MLB, respectively. The rate of knee injury was similar and not significantly different between the MiLB and MLB (1.2 per 1000 AE in the MiLB and 1.1 per 1000 AE in the MLB).

Characteristics of Injuries

When considering the position of the player during injury, defensive players were most frequently injured (n = 742, 56.5%), with pitchers (n = 227, 17.3%), infielders (n =193, 14.7%), outfielders (n = 193, 14.7%), and catchers (n = 129, 9.8%) sustaining injuries in decreasing frequency. Injuries while on offense (n = 571, 43.5%) were most frequent in base runners (n = 320, 24.4%) followed by batters (n = 251, 19.1%) (Table 4). Injuries while on defense occurring in infielders and catchers resulted in the longest period of time away from play (average of 22.4 and 20.8 days missed, respectively), while those occurring in batters resulted in the least average days missed (8.9 days).

The most common field location for knee injuries to occur was the infield, which was responsible for n = 647 (29.8%) of the total knee injuries (Table 4). This was followed by home plate (n = 493, 22.7%), other locations outside those specified (n = 394, 18.1%), outfield (n = 320, 14.7%), pitcher’s mound (n = 210, 9.7%), and foul territory or the bullpen (n = 107, 4.9%). Of the knee injuries with a specified location, those occurring in foul territory or the bullpen resulted in the highest mean days missed (18.4), while those occurring at home plate resulted in the least mean days missed (13.4 days).

When analyzed by mechanism of injury, noncontact injuries (n = 953, 43.9%) were more common than being hit with the ball (n = 374, 17.2%), striking the ground (n = 409, 18.8%), other mechanisms not listed (n = 196, 9%), contact with another player (n = 176, 8.1%), or contact with other objects (n = 63, 2.9%) (Table 4). Noncontact injuries and player to player collisions resulted in the greatest number of missed days (21.6 and 17.1 days, respectively) while being struck by the ball resulted in the least mean days missed (5.1).

Of the n = 493 knee injuries occurring at home plate, n = 212 (43%) occurred to the batter, n = 100 (20%) to the catcher, n = 34 (6.9%) to base runners, and n = 7 (1.4%) to pitchers (Table 5). The majority of knee injuries in the infield occurred to base runners (n = 283, 43.7%). Player-to-player collisions at home plate were responsible for 51 (2.3%) knee injuries, while 163 (24%) were noncontact injuries and 376 (56%) were the result of a player being hit by the ball (Table 5).

Injury Diagnosis

By diagnosis, the most common knee injuries observed were contusions or hematomas (n = 662, 30.5%), other injuries (n = 415, 19.1%), sprains or ligament injuries (n = 380, 17.5%), tendinopathies or bursitis (n = 367, 16.9%), and meniscal or cartilage injury (n = 200, 9.2%) (Table 6). Injuries resulting in the greatest mean number of days missed included meniscal or cartilage injuries (44 days), sprains or ligament injuries (30 days), or dislocations (22 days).

Based on specific SMDCS descriptors, the most frequent knee injuries reported were contusion (n = 662, 30.5%), patella tendinopathy (n = 222, 10.2%), and meniscal tears (n = 200, 9.2%) (Table 6). Complete anterior cruciate ligament tears, although infrequent, were responsible for the greatest mean days missed (156.2 days). This was followed by lateral meniscus tears (47.5 days) and medial meniscus tears (41.2 days). Knee contusions, although very common, resulted in the least number of days missed (6.0 days).

Discussion

Although much is known about knee injuries in other professional athletic leagues, little is known about knee injuries in professional baseball players.^2-4 The majority of epidemiologic studies regarding baseball players at any level emphasizes the study of shoulder and elbow injuries.^3,4,19 Since the implementation of the electronic medical record and the HITS database in professional baseball, there has been increased effort to document injuries that have received less attention in the existing literature. Understanding the epidemiology of these injuries is important for the development of targeted prevention efforts.

Prior studies of injuries in professional baseball relied on data captured by the publicly available DL. Posner and colleagues² provide one of the most comprehensive reports on MLB injuries in a report utilizing DL assignment data over a period of 7 seasons.They demonstrated that knee injuries were responsible for 7.7% (12.5% for fielders and 3.7% for pitchers) of assignments to the DL. The current study utilized a comprehensive surveillance and builds on this existing knowledge. The present study found similar trends to Posner and colleagues² in that knee injuries were responsible for 6.5% of injuries in professional baseball players that resulted in missed games. From the 2002 season to the 2008 season, knee injuries were the fifth most common reason MLB players were placed on the DL,² and the current study indicates that they remain the fifth most common reason for missed time from play based on the HITS data. Since the prevalence of these injuries have remained constant since the 2002 season, efforts to better understand these injuries are warranted in order to identify strategies to prevent them. These analyses have generated important data towards achieving this understanding.

As with most injuries in professional sports, goals for treatment are aimed at maximizing patient function and performance while minimizing time out of play. For the 2011-2014 professional baseball seasons, a total of 2171 players sustained knee injuries and missed an average of 16.2 days per injury. Knee injuries were responsible for a total of 7612 days of missed work for MLB and MiLB players per season (30,449 days over the 4-season study period). This is equivalent to a total of 20.9 years of players’ time lost in professional baseball per season over the last 4 years. The implications of this amount of time away from sport are significant, and further study should be targeted at prevention of these injuries and optimizing return to play times.

When attempting to reduce the burden of knee injuries in professional baseball, it may prove beneficial to first understand how the injuries occur, where on the field, and who is at greatest risk. From 2011 to 2014, nearly 44% of knee injuries occurred by noncontact mechanisms. Among all locations on the field where knee injuries occurred, those occurring in the infield were responsible for the greatest mean days missed. The players who seem to be at greatest risk for knee injuries appear to be base runners. These data suggest the need for prevention efforts targeting base runners and infield players, as well as players in MiLB, where the largest number of injuries occurred.

Recently, playing rules implemented by MLB after consultation with players have focused on reducing the number of player-to-player collisions at home plate in an attempt to decrease the injury burden to catchers and base runners.²⁰ This present analysis suggests that this rule change may also reduce the occurrence of knee injuries, as player collisions at home plate were responsible for a total of 51 knee injuries during the study period. The impact of this rule change on injury rates should also be explored. Interestingly, of the 51 knees injuries occurring due to contact at home plate, 23 occurred in 2011, and only 2 occurred in 2014—the first year of the new rule. Additional areas that resulted in high numbers of knee injuries were player-to-player contact in the infield and player contact with the ground in the infield.

Attempting to reduce injury burden and time out of play related to knee injuries in professional baseball players will likely prove to be a difficult task. In order to generate meaningful improvement, a comprehensive approach that involves players, management, trainers, therapists, and physicians will likely be required. As the first report of the epidemiology of knee injuries in professional baseball players, this study is one important step in that process. The strengths of this study are its comprehensive nature that analyzes injuries from an entire population of players on more than 200 teams over a 3-year period. Also, this research is strengthened by its focus on one particular region of the body that has received limited attention in the empirical literature, but represents a significant source of lost time during the baseball season.

There are some limitations to this study. As with any injury surveillance system, there is the possibility that not all cases were captured. Additionally, since the surveillance system is based on data from multiple teams, data entry discrepancy is possible; however, the presence of dropdown boxes and systematic definitions for injuries reduces this risk. Finally, this study did not investigate the various treatments for knee injuries beyond whether or not the injury required surgery. Since this was the first comprehensive exploration of knee injuries in professional baseball, future studies are needed to explore additional facets including outcomes related to treatment, return to play, and performance.

Conclusion

Knee injuries represent 6.5% of all injuries in professional baseball, occurring at a rate of 1.3 per 1000 AE. The burden of these injuries is significant for professional baseball players. This study fills a critical gap in sports injury research by contributing to the knowledge about the effect of knee injuries in professional baseball. It also provides an important foundation for future epidemiologic inquiry to identify modifiable risk factors and interventions that may reduce the impact of these injuries in athletes.

Injuries among professional baseball players have been on the rise for several years.^1,2 From 1989 to 1999, the number of disabled list (DL) reports increased 38% (266 to 367 annual reports),¹ and a similar increase in injury rates was noted from the 2002 to the 2008 seasons (37%).² These injuries have important implications for future injury risk and time away from play. Identifying these injuries and determining correlates and risk factors is important for targeted prevention efforts.

Several studies have explored the prevalence of upper extremity injuries in professional and collegiate baseball players;^2-4 however, detailed epidemiology of knee injuries in Major League Baseball (MLB) and Minor League Baseball (MiLB) players is lacking. Much more is known about the prevalence, treatment, and outcomes of knee injuries in other professional sporting organizations, such as the National Basketball Association (NBA), National Football League (NFL), and National Hockey League (NHL).^4-12 A recent meta-analysis exploring injuries in professional athletes found that studies on lower extremity injuries comprised approximately 12% of the literature reporting injuries in MLB players.⁴ In other professional leagues, publications on lower extremity injuries comprise approximately 56% of the sports medicine literature in the NFL, 54% in the NBA, and 62% in the NHL.⁴ Since few studies have investigated lower extremity injuries among professional baseball players, there is an opportunity for additional research to guide evidence-based prevention strategies.

A better understanding of the nature of these injuries is one of the first steps towards developing targeted injury prevention programs and treatment algorithms. The study of injury epidemiology among professional baseball players has been aided by the creation of an injury tracking system initiated by the MLB, its minor league affiliates, and the Major League Baseball Players Association.^5,13,14 This surveillance system allows for the tracking of medical histories and injuries to players as they move across major and minor league organizations. Similar systems have been utilized in the National Collegiate Athletic Association and other professional sports organizations.^3,15-17 A unique advantage of the MLB surveillance system is the required participation of all major and minor league teams, which allows for investigation of the entire population of players rather than simply a sample of players from select teams. This system has propelled an effort to identify injury patterns as a means of developing appropriate targets for potential preventative measures.⁵

The purpose of this descriptive epidemiologic study is to better understand the distribution and characteristics of knee injuries in these elite athletes by reporting on all knee injuries occurring over a span of 4 seasons (2011-2014). Additionally, this study seeks to characterize the impact of these injuries by analyzing the time required for return to play and the treatments rendered (surgical and nonsurgical).

Materials and Methods

After approval from the Johns Hopkins Bloomberg School of Public Health Institutional Review Board, detailed data regarding knee injuries in both MLB and MiLB baseball players were extracted from the de-identified MLB Health and Injury Tracking System (HITS). The HITS database is a centralized database that contains data on injuries from an electronic medical record (EMR). All players provided consent to have their data included in this EMR. HITS system captures injuries reported by the athletic trainers for all professional baseball players from 30 MLB clubs and their 230 minor league affiliates. Additional details on this population of professional baseball players have been published elsewhere.⁵ Only injuries that result in time out of play (≥1 day missed) are included in the database, and they are logged with basic information such as region of the body, diagnosis, date, player position, activity leading to injury, and general treatment. Any injury that affects participation in any aspect of baseball-related activity (eg, game, practice, warm-up, conditioning, weight training) is captured in HITS.

All baseball-related knee injuries occurring during the 2011-2014 seasons that resulted in time out of sport were included in the study. These injuries were identified based on the Sports Medicine Diagnostic Coding System (SMDCS) to capture injuries by diagnostic groups.¹⁸ Knee injuries were included if they occurred during spring training, regular season, or postseason play. Offseason injuries were not included. Injury events that were classified as “season-ending” were not included in the analysis of days missed because many of these players may not have been cleared to play until the beginning of the following season. To determine the proportion of knee injuries during the study period, all injuries were included for comparative purposes (subdivided based on 30 anatomic regions or types).

For each knee injury, a number of variables were analyzed, including diagnosis, level of play (MLB vs. MiLB), age, player position at the time of injury (pitcher, catcher, infield, outfield, base runner, or batter), field location where the injury occurred (home plate, pitcher’s mound, infield, outfield, foul territory or bullpen, or other), mechanism of injury, days missed, and treatment rendered (conservative vs surgical). The classification used to describe the mechanism of injury consisted of contact with ball, contact with ground, contact with another player, contact with another object, or noncontact.

Statistical Analysis
Epidemiologic data are presented with descriptive statistics such as mean, median, frequency, and percentage where appropriate. When comparing player age, days missed, and surgical vs nonsurgical treatment between MLB and MiLB players, t-tests and tests for difference in proportions were applied as appropriate. Statistical significance was established for P values < .05.

The distribution of days missed for the variables considered was often skewed to the right (ie, days missed mostly concentrated on the low to moderate number of days, with fewer values in the much higher days missed range), even after excluding the season-ending injuries; hence the mean (or average) days missed was often larger than the median days missed. Reporting the median would allow for a robust estimate of the expected number of days missed, but would down weight those instances when knee injuries result in much longer missed days, as reflected by the mean. Because of the importance of the days missed measure for professional baseball, both the mean and median are presented.

In order to estimate exposure, the average number of players per team per game was calculated based on analysis of regular season game participation via box scores. This average number over a season, multiplied by the number of team games at each professional level of baseball, was used as an estimate of athlete exposures in order to provide rates comparable to those of other injury surveillance systems. Injury rates were reported as injuries per 1000 athlete-exposures (AE) for those knee injuries that occurred during the regular season. It should be noted that the number of regular season knee injuries and the subsequent AE rates are based on injuries that were deemed work-related during the regular season. This does not necessarily only include injuries occurring during the course of a game, but injuries in game preparation as well. Due to the variations in spring training games and fluctuating rosters, an exposure rate could not be calculated for spring training knee injuries.

RESULTS

Overall Summary

Of the 30 general body regions/systems included in the HITS database, injuries to the knee were the fifth most common reason for days missed in all of professional baseball from 2011-2014 (Table 1). Injuries to the knee represented 6.5% of the nearly 34,000 injuries sustained during the study period. Knee injuries were the fifth most common reason for time out of play for players in both the MiLB and MLB.

A total of 2171 isolated knee injuries resulted in time out of sport for professional baseball players (Table 2). Of these, 410 (19%) occurred in MLB players and 1761 (81%) occurred in MiLB players. MLB players were older than MiLB players at the time of injury (29.5 vs 22.8 years, respectively). Overall mean number of days missed was 16.2 days per knee injury, with MLB players missing an approximately 7 days more per injury than MiLB athletes (21.8 vs. 14.9 days respectively; P = .001).Over the course of the 4 seasons, a total of 30,449 days were missed due to knee injuries in professional baseball, giving an average rate of 7612 days lost per season. Surgery was performed for 263 (12.1%) of the 2171 knee injuries, with a greater proportion of MLB players requiring surgery than MiLB players (17.3% vs 10.9%) (P < .001). With respect to number of days missed per injury, 26% of knee injuries in the minor leagues resulted in greater than 30 days missed, while this number rose to 32% for knee injuries in MLB players (Table 3).

For regular season games, it was estimated that there were 1,197,738 MiLB and 276,608 MLB AE, respectively, over the course of the 4 seasons (2011-2014). The overall knee injury rate across both the MiLB and MLB was 1.2 per 1000 AE, based on the subset of 308 and 1473 regular season knee injuries in MiLB and MLB, respectively. The rate of knee injury was similar and not significantly different between the MiLB and MLB (1.2 per 1000 AE in the MiLB and 1.1 per 1000 AE in the MLB).

Characteristics of Injuries

When considering the position of the player during injury, defensive players were most frequently injured (n = 742, 56.5%), with pitchers (n = 227, 17.3%), infielders (n =193, 14.7%), outfielders (n = 193, 14.7%), and catchers (n = 129, 9.8%) sustaining injuries in decreasing frequency. Injuries while on offense (n = 571, 43.5%) were most frequent in base runners (n = 320, 24.4%) followed by batters (n = 251, 19.1%) (Table 4). Injuries while on defense occurring in infielders and catchers resulted in the longest period of time away from play (average of 22.4 and 20.8 days missed, respectively), while those occurring in batters resulted in the least average days missed (8.9 days).

The most common field location for knee injuries to occur was the infield, which was responsible for n = 647 (29.8%) of the total knee injuries (Table 4). This was followed by home plate (n = 493, 22.7%), other locations outside those specified (n = 394, 18.1%), outfield (n = 320, 14.7%), pitcher’s mound (n = 210, 9.7%), and foul territory or the bullpen (n = 107, 4.9%). Of the knee injuries with a specified location, those occurring in foul territory or the bullpen resulted in the highest mean days missed (18.4), while those occurring at home plate resulted in the least mean days missed (13.4 days).

When analyzed by mechanism of injury, noncontact injuries (n = 953, 43.9%) were more common than being hit with the ball (n = 374, 17.2%), striking the ground (n = 409, 18.8%), other mechanisms not listed (n = 196, 9%), contact with another player (n = 176, 8.1%), or contact with other objects (n = 63, 2.9%) (Table 4). Noncontact injuries and player to player collisions resulted in the greatest number of missed days (21.6 and 17.1 days, respectively) while being struck by the ball resulted in the least mean days missed (5.1).

Of the n = 493 knee injuries occurring at home plate, n = 212 (43%) occurred to the batter, n = 100 (20%) to the catcher, n = 34 (6.9%) to base runners, and n = 7 (1.4%) to pitchers (Table 5). The majority of knee injuries in the infield occurred to base runners (n = 283, 43.7%). Player-to-player collisions at home plate were responsible for 51 (2.3%) knee injuries, while 163 (24%) were noncontact injuries and 376 (56%) were the result of a player being hit by the ball (Table 5).

Injury Diagnosis

By diagnosis, the most common knee injuries observed were contusions or hematomas (n = 662, 30.5%), other injuries (n = 415, 19.1%), sprains or ligament injuries (n = 380, 17.5%), tendinopathies or bursitis (n = 367, 16.9%), and meniscal or cartilage injury (n = 200, 9.2%) (Table 6). Injuries resulting in the greatest mean number of days missed included meniscal or cartilage injuries (44 days), sprains or ligament injuries (30 days), or dislocations (22 days).

Based on specific SMDCS descriptors, the most frequent knee injuries reported were contusion (n = 662, 30.5%), patella tendinopathy (n = 222, 10.2%), and meniscal tears (n = 200, 9.2%) (Table 6). Complete anterior cruciate ligament tears, although infrequent, were responsible for the greatest mean days missed (156.2 days). This was followed by lateral meniscus tears (47.5 days) and medial meniscus tears (41.2 days). Knee contusions, although very common, resulted in the least number of days missed (6.0 days).

Discussion

Although much is known about knee injuries in other professional athletic leagues, little is known about knee injuries in professional baseball players.^2-4 The majority of epidemiologic studies regarding baseball players at any level emphasizes the study of shoulder and elbow injuries.^3,4,19 Since the implementation of the electronic medical record and the HITS database in professional baseball, there has been increased effort to document injuries that have received less attention in the existing literature. Understanding the epidemiology of these injuries is important for the development of targeted prevention efforts.

Prior studies of injuries in professional baseball relied on data captured by the publicly available DL. Posner and colleagues² provide one of the most comprehensive reports on MLB injuries in a report utilizing DL assignment data over a period of 7 seasons.They demonstrated that knee injuries were responsible for 7.7% (12.5% for fielders and 3.7% for pitchers) of assignments to the DL. The current study utilized a comprehensive surveillance and builds on this existing knowledge. The present study found similar trends to Posner and colleagues² in that knee injuries were responsible for 6.5% of injuries in professional baseball players that resulted in missed games. From the 2002 season to the 2008 season, knee injuries were the fifth most common reason MLB players were placed on the DL,² and the current study indicates that they remain the fifth most common reason for missed time from play based on the HITS data. Since the prevalence of these injuries have remained constant since the 2002 season, efforts to better understand these injuries are warranted in order to identify strategies to prevent them. These analyses have generated important data towards achieving this understanding.

As with most injuries in professional sports, goals for treatment are aimed at maximizing patient function and performance while minimizing time out of play. For the 2011-2014 professional baseball seasons, a total of 2171 players sustained knee injuries and missed an average of 16.2 days per injury. Knee injuries were responsible for a total of 7612 days of missed work for MLB and MiLB players per season (30,449 days over the 4-season study period). This is equivalent to a total of 20.9 years of players’ time lost in professional baseball per season over the last 4 years. The implications of this amount of time away from sport are significant, and further study should be targeted at prevention of these injuries and optimizing return to play times.

When attempting to reduce the burden of knee injuries in professional baseball, it may prove beneficial to first understand how the injuries occur, where on the field, and who is at greatest risk. From 2011 to 2014, nearly 44% of knee injuries occurred by noncontact mechanisms. Among all locations on the field where knee injuries occurred, those occurring in the infield were responsible for the greatest mean days missed. The players who seem to be at greatest risk for knee injuries appear to be base runners. These data suggest the need for prevention efforts targeting base runners and infield players, as well as players in MiLB, where the largest number of injuries occurred.

Recently, playing rules implemented by MLB after consultation with players have focused on reducing the number of player-to-player collisions at home plate in an attempt to decrease the injury burden to catchers and base runners.²⁰ This present analysis suggests that this rule change may also reduce the occurrence of knee injuries, as player collisions at home plate were responsible for a total of 51 knee injuries during the study period. The impact of this rule change on injury rates should also be explored. Interestingly, of the 51 knees injuries occurring due to contact at home plate, 23 occurred in 2011, and only 2 occurred in 2014—the first year of the new rule. Additional areas that resulted in high numbers of knee injuries were player-to-player contact in the infield and player contact with the ground in the infield.

Attempting to reduce injury burden and time out of play related to knee injuries in professional baseball players will likely prove to be a difficult task. In order to generate meaningful improvement, a comprehensive approach that involves players, management, trainers, therapists, and physicians will likely be required. As the first report of the epidemiology of knee injuries in professional baseball players, this study is one important step in that process. The strengths of this study are its comprehensive nature that analyzes injuries from an entire population of players on more than 200 teams over a 3-year period. Also, this research is strengthened by its focus on one particular region of the body that has received limited attention in the empirical literature, but represents a significant source of lost time during the baseball season.

There are some limitations to this study. As with any injury surveillance system, there is the possibility that not all cases were captured. Additionally, since the surveillance system is based on data from multiple teams, data entry discrepancy is possible; however, the presence of dropdown boxes and systematic definitions for injuries reduces this risk. Finally, this study did not investigate the various treatments for knee injuries beyond whether or not the injury required surgery. Since this was the first comprehensive exploration of knee injuries in professional baseball, future studies are needed to explore additional facets including outcomes related to treatment, return to play, and performance.

Conclusion

Knee injuries represent 6.5% of all injuries in professional baseball, occurring at a rate of 1.3 per 1000 AE. The burden of these injuries is significant for professional baseball players. This study fills a critical gap in sports injury research by contributing to the knowledge about the effect of knee injuries in professional baseball. It also provides an important foundation for future epidemiologic inquiry to identify modifiable risk factors and interventions that may reduce the impact of these injuries in athletes.

LOS ANGELES – In asymptomatic patients under 80 years old, carotid stenting and endarterectomy perform equally as well for severe carotid stenosis out to 5 years, according to a randomized trial published online in the New England Journal of Medicine.

Overall, 1,032 patients were stented, and 343 had endarterectomies in the trial, called Asymptomatic Carotid Trial I (ACT I). If stenting didn’t look safe on postrandomization angiography, patients were given the option of medical management or crossover into the surgical group. The subjects all had bifurcation carotid stenosis blocking at least 70% of the lumen. None were at high risk for surgical complications. “Asymptomatic” meant they hadn’t had a stroke, transient ischemic attack, or amaurosis fugax in the 6 months before enrollment. Stenting and endarterectomy were done by physicians and centers well experienced in the techniques (N Engl J Med. 2016 Feb 17. doi: 10.1056/NEJMoa1515706).

At 1 year, stenting was noninferior to endarterectomy for the primary composite endpoint of death, stroke, or myocardial infarction within 30 days after the procedure or ipsilateral stroke within 1 year; the event rate was 3.8% among stent patients and 3.4% among endarterectomy patients (P = .01 for noninferiority, with a noninferiority margin of 3 percentage points).

The cumulative 5-year stroke-free survival rate was 93.1% in the stenting group and 94.7% in the endarterectomy group (P = .44).

For now, the results mean that sometimes choosing between carotid endarterectomy or stenting (or medical management) has as much to do with patient and physician preference as medical science, raising the difficult question of how to choose. In a video interview at the International Stroke Conference, investigator Dr. Lawrence Wechsler, professor of neurology/neurosurgery and chair of the department of neurology at the University of Pittsburgh, shared his thoughts on that and the other implications of the study. The work was funded by Abbott Vascular.

[email protected]

LOS ANGELES – In asymptomatic patients under 80 years old, carotid stenting and endarterectomy perform equally as well for severe carotid stenosis out to 5 years, according to a randomized trial published online in the New England Journal of Medicine.

Overall, 1,032 patients were stented, and 343 had endarterectomies in the trial, called Asymptomatic Carotid Trial I (ACT I). If stenting didn’t look safe on postrandomization angiography, patients were given the option of medical management or crossover into the surgical group. The subjects all had bifurcation carotid stenosis blocking at least 70% of the lumen. None were at high risk for surgical complications. “Asymptomatic” meant they hadn’t had a stroke, transient ischemic attack, or amaurosis fugax in the 6 months before enrollment. Stenting and endarterectomy were done by physicians and centers well experienced in the techniques (N Engl J Med. 2016 Feb 17. doi: 10.1056/NEJMoa1515706).

At 1 year, stenting was noninferior to endarterectomy for the primary composite endpoint of death, stroke, or myocardial infarction within 30 days after the procedure or ipsilateral stroke within 1 year; the event rate was 3.8% among stent patients and 3.4% among endarterectomy patients (P = .01 for noninferiority, with a noninferiority margin of 3 percentage points).

The cumulative 5-year stroke-free survival rate was 93.1% in the stenting group and 94.7% in the endarterectomy group (P = .44).

For now, the results mean that sometimes choosing between carotid endarterectomy or stenting (or medical management) has as much to do with patient and physician preference as medical science, raising the difficult question of how to choose. In a video interview at the International Stroke Conference, investigator Dr. Lawrence Wechsler, professor of neurology/neurosurgery and chair of the department of neurology at the University of Pittsburgh, shared his thoughts on that and the other implications of the study. The work was funded by Abbott Vascular.

[email protected]

LOS ANGELES – In asymptomatic patients under 80 years old, carotid stenting and endarterectomy perform equally as well for severe carotid stenosis out to 5 years, according to a randomized trial published online in the New England Journal of Medicine.

Overall, 1,032 patients were stented, and 343 had endarterectomies in the trial, called Asymptomatic Carotid Trial I (ACT I). If stenting didn’t look safe on postrandomization angiography, patients were given the option of medical management or crossover into the surgical group. The subjects all had bifurcation carotid stenosis blocking at least 70% of the lumen. None were at high risk for surgical complications. “Asymptomatic” meant they hadn’t had a stroke, transient ischemic attack, or amaurosis fugax in the 6 months before enrollment. Stenting and endarterectomy were done by physicians and centers well experienced in the techniques (N Engl J Med. 2016 Feb 17. doi: 10.1056/NEJMoa1515706).

At 1 year, stenting was noninferior to endarterectomy for the primary composite endpoint of death, stroke, or myocardial infarction within 30 days after the procedure or ipsilateral stroke within 1 year; the event rate was 3.8% among stent patients and 3.4% among endarterectomy patients (P = .01 for noninferiority, with a noninferiority margin of 3 percentage points).

The cumulative 5-year stroke-free survival rate was 93.1% in the stenting group and 94.7% in the endarterectomy group (P = .44).

For now, the results mean that sometimes choosing between carotid endarterectomy or stenting (or medical management) has as much to do with patient and physician preference as medical science, raising the difficult question of how to choose. In a video interview at the International Stroke Conference, investigator Dr. Lawrence Wechsler, professor of neurology/neurosurgery and chair of the department of neurology at the University of Pittsburgh, shared his thoughts on that and the other implications of the study. The work was funded by Abbott Vascular.

[email protected]

The Diagnosis: Cutaneous Larva Migrans

Three punch biopsies were obtained. Spongiotic dermatitis with eosinophils was seen. There was a single specimen of tissue that showed a possible intraepidermal larva with a tract in the epidermis. The differential diagnosis included allergic contact dermatitis and arthropod bite eruption, among others, but clinical correlation made cutaneous larva migrans (CLM) the likely diagnosis.

The patient was treated empirically with albendazole 400 mg once daily for 3 days. In addition, he was prescribed triamcinolone for symptomatic relief and remained asymptomatic for 8 weeks at which time he presented again to the dermatology clinic with a similar rash in the same distribution. He was treated with a repeat course of albendazole and further educated on the etiology of the infection. The patient has not exhibited a recurrence after treatment of the second episode of CLM.

Cutaneous larva migrans is a dermatosis of the skin caused by the larvae of parasitic nematodes from the hookworm family, most commonly Ancylostoma caninum and Ancylostoma braziliense.^1,2 These hookworms thrive in warm moist climates and are most frequently found in tropical coastal regions. They normally inhabit the intestines of animals such as dogs and cats and are transmitted to soil and sand via feces. Humans become accidental hosts through contact with the contaminated sand or soil³; however, the larvae are unable to penetrate deeper than the upper dermis of the skin in humans, subsequently limiting the infection. Because humans are accidental hosts, the larvae are unable to complete their life cycle and larval death occurs within weeks to months after the initial infection³; thus treatment may be unnecessary unless complications arise.

Cutaneous larva migrans is most commonly observed in travelers or inhabitants of tropical coastal regions but can occur anywhere in the world.¹ Clinically, CLM presents as an enlarging, intensely pruritic, erythematous linear or serpiginous tract,³ most commonly on the hands, feet, abdomen, and buttocks.¹ Complications may include allergic reactions, secondary bacterial infections, and hookworm folliculitis.⁴ Although rare, migration to the intestinal tract⁵ and/or hematological spread with Löffler syndrome has been described.⁶ Although this dermatological disease has been well described in the medical literature, it is not well recognized by Western physicians and is consequently either not diagnosed or misdiagnosed, leading to delays in treatment.⁴ Although the infection is usually self-limiting without treatment, the risk for prolonged active disease may occur, with 1 reported case lasting up to 18 months.^4,5 The first indicator of CLM is intense pruritus localized to the site of infection.⁴ As the larvae migrate or creep, they create a lesion that may appear edematous with vesiculobullous lesions that are either serpiginous or linear.⁴ The differential diagnosis may include fungal infection, bacterial infection, and atypical herpes simplex infections; however, the key finding in CLM is the presence of undulating tracts localized to the borders of the lesion.² Patients may report experiencing a stinging sensation prior to the formation of the erythematous scaly papule,⁵ which is attributed to the initial penetration of the larva into the skin. This development, accompanied with a history of travel to tropical or subtropical regions, should elicit CLM as a likely diagnosis. Because hookworms are a type of helminth, they likely elicit an eosinophilic immune response and thus peripheral eosinophilia may be present.⁵

Effective treatment of CLM is accomplished with oral albendazole 400 mg once daily for 3 to 7 days.^2,7 Alternatively, oral ivermectin, topical thiabendazole, and cryosurgery can be used,² though albendazole currently is the preferred treatment of CLM.⁷

The Diagnosis: Cutaneous Larva Migrans

Three punch biopsies were obtained. Spongiotic dermatitis with eosinophils was seen. There was a single specimen of tissue that showed a possible intraepidermal larva with a tract in the epidermis. The differential diagnosis included allergic contact dermatitis and arthropod bite eruption, among others, but clinical correlation made cutaneous larva migrans (CLM) the likely diagnosis.

The patient was treated empirically with albendazole 400 mg once daily for 3 days. In addition, he was prescribed triamcinolone for symptomatic relief and remained asymptomatic for 8 weeks at which time he presented again to the dermatology clinic with a similar rash in the same distribution. He was treated with a repeat course of albendazole and further educated on the etiology of the infection. The patient has not exhibited a recurrence after treatment of the second episode of CLM.

Cutaneous larva migrans is a dermatosis of the skin caused by the larvae of parasitic nematodes from the hookworm family, most commonly Ancylostoma caninum and Ancylostoma braziliense.^1,2 These hookworms thrive in warm moist climates and are most frequently found in tropical coastal regions. They normally inhabit the intestines of animals such as dogs and cats and are transmitted to soil and sand via feces. Humans become accidental hosts through contact with the contaminated sand or soil³; however, the larvae are unable to penetrate deeper than the upper dermis of the skin in humans, subsequently limiting the infection. Because humans are accidental hosts, the larvae are unable to complete their life cycle and larval death occurs within weeks to months after the initial infection³; thus treatment may be unnecessary unless complications arise.

Cutaneous larva migrans is most commonly observed in travelers or inhabitants of tropical coastal regions but can occur anywhere in the world.¹ Clinically, CLM presents as an enlarging, intensely pruritic, erythematous linear or serpiginous tract,³ most commonly on the hands, feet, abdomen, and buttocks.¹ Complications may include allergic reactions, secondary bacterial infections, and hookworm folliculitis.⁴ Although rare, migration to the intestinal tract⁵ and/or hematological spread with Löffler syndrome has been described.⁶ Although this dermatological disease has been well described in the medical literature, it is not well recognized by Western physicians and is consequently either not diagnosed or misdiagnosed, leading to delays in treatment.⁴ Although the infection is usually self-limiting without treatment, the risk for prolonged active disease may occur, with 1 reported case lasting up to 18 months.^4,5 The first indicator of CLM is intense pruritus localized to the site of infection.⁴ As the larvae migrate or creep, they create a lesion that may appear edematous with vesiculobullous lesions that are either serpiginous or linear.⁴ The differential diagnosis may include fungal infection, bacterial infection, and atypical herpes simplex infections; however, the key finding in CLM is the presence of undulating tracts localized to the borders of the lesion.² Patients may report experiencing a stinging sensation prior to the formation of the erythematous scaly papule,⁵ which is attributed to the initial penetration of the larva into the skin. This development, accompanied with a history of travel to tropical or subtropical regions, should elicit CLM as a likely diagnosis. Because hookworms are a type of helminth, they likely elicit an eosinophilic immune response and thus peripheral eosinophilia may be present.⁵

Effective treatment of CLM is accomplished with oral albendazole 400 mg once daily for 3 to 7 days.^2,7 Alternatively, oral ivermectin, topical thiabendazole, and cryosurgery can be used,² though albendazole currently is the preferred treatment of CLM.⁷

The Diagnosis: Cutaneous Larva Migrans

Three punch biopsies were obtained. Spongiotic dermatitis with eosinophils was seen. There was a single specimen of tissue that showed a possible intraepidermal larva with a tract in the epidermis. The differential diagnosis included allergic contact dermatitis and arthropod bite eruption, among others, but clinical correlation made cutaneous larva migrans (CLM) the likely diagnosis.

The patient was treated empirically with albendazole 400 mg once daily for 3 days. In addition, he was prescribed triamcinolone for symptomatic relief and remained asymptomatic for 8 weeks at which time he presented again to the dermatology clinic with a similar rash in the same distribution. He was treated with a repeat course of albendazole and further educated on the etiology of the infection. The patient has not exhibited a recurrence after treatment of the second episode of CLM.

Cutaneous larva migrans is a dermatosis of the skin caused by the larvae of parasitic nematodes from the hookworm family, most commonly Ancylostoma caninum and Ancylostoma braziliense.^1,2 These hookworms thrive in warm moist climates and are most frequently found in tropical coastal regions. They normally inhabit the intestines of animals such as dogs and cats and are transmitted to soil and sand via feces. Humans become accidental hosts through contact with the contaminated sand or soil³; however, the larvae are unable to penetrate deeper than the upper dermis of the skin in humans, subsequently limiting the infection. Because humans are accidental hosts, the larvae are unable to complete their life cycle and larval death occurs within weeks to months after the initial infection³; thus treatment may be unnecessary unless complications arise.

Cutaneous larva migrans is most commonly observed in travelers or inhabitants of tropical coastal regions but can occur anywhere in the world.¹ Clinically, CLM presents as an enlarging, intensely pruritic, erythematous linear or serpiginous tract,³ most commonly on the hands, feet, abdomen, and buttocks.¹ Complications may include allergic reactions, secondary bacterial infections, and hookworm folliculitis.⁴ Although rare, migration to the intestinal tract⁵ and/or hematological spread with Löffler syndrome has been described.⁶ Although this dermatological disease has been well described in the medical literature, it is not well recognized by Western physicians and is consequently either not diagnosed or misdiagnosed, leading to delays in treatment.⁴ Although the infection is usually self-limiting without treatment, the risk for prolonged active disease may occur, with 1 reported case lasting up to 18 months.^4,5 The first indicator of CLM is intense pruritus localized to the site of infection.⁴ As the larvae migrate or creep, they create a lesion that may appear edematous with vesiculobullous lesions that are either serpiginous or linear.⁴ The differential diagnosis may include fungal infection, bacterial infection, and atypical herpes simplex infections; however, the key finding in CLM is the presence of undulating tracts localized to the borders of the lesion.² Patients may report experiencing a stinging sensation prior to the formation of the erythematous scaly papule,⁵ which is attributed to the initial penetration of the larva into the skin. This development, accompanied with a history of travel to tropical or subtropical regions, should elicit CLM as a likely diagnosis. Because hookworms are a type of helminth, they likely elicit an eosinophilic immune response and thus peripheral eosinophilia may be present.⁵

Effective treatment of CLM is accomplished with oral albendazole 400 mg once daily for 3 to 7 days.^2,7 Alternatively, oral ivermectin, topical thiabendazole, and cryosurgery can be used,² though albendazole currently is the preferred treatment of CLM.⁷

NEW ORLEANS—Levels of anti-Mullerian hormone, a marker of the perimenopausal period, are associated with total gray matter volume and disability in patients with multiple sclerosis (MS), independent of chronological age and disease duration, according to data presented at the ACTRIMS 2016 Forum. The study also indicates that women with MS have no reduction in follicular reserve, compared with healthy women, and therefore have normal fertility.

Women with MS tend to have a more benign initial course than men with MS do, but the former often transition to secondary progressive disease near the time of menopause. To date, research has not clarified whether ovarian decline contributes to the accumulation of disability in women with MS.

Jennifer S. Graves, MD, PhD, a neurologist at the University of California, San Francisco Medical Center, and colleagues initiated a study to determine whether ovarian decline, as measured by levels of anti-Mullerian hormone, is associated with clinical disability or brain atrophy in women with MS. They examined 412 women with MS (mean age, 42.6) and 180 healthy controls (mean age, 44) from a longitudinal research cohort that had as many as 10 years of clinical and MRI follow-up. The investigators measured anti-Mullerian hormone levels in batch using a highly sensitive enzyme-linked immunosorbent assay on plasma samples from baseline, year 3, year 5, and years 8 to 10. They analyzed the data with logistic, linear, and mixed-model regression techniques, with adjustments for age, disease duration, smoking, race, ethnicity, vitamin D level, disease modifying therapy, birth control, and hormone replacement therapy as appropriate.

Jennifer S. Graves, MD, PhD

Dr. Graves and colleagues found that in models controlling for age, anti-Mullerian hormone levels were similar in women with MS and healthy controls. In a multivariable model of women with MS, including rigorous adjustments for age and disease duration, ovarian reserve (per twofold decrease in anti-Mullerian hormone pg/mL) was associated with total normalized gray matter volume (β = -3.29 mm³) and MS Functional Composite z-scores (β = -0.060) at baseline. After adjustment for age, white matter volumes were also associated with anti-Mullerian hormone levels (β = -2.64 mm³) at baseline, but the association did not remain statistically significant after additional adjustments (β = -1.49 mm³).

Having undetectable levels of anti-Mullerian hormone (28% of subjects) was associated with 0.60-point higher Expanded Disability Status Scale score. In a multivariable random-intercept-random-slope model using all observations over time, a twofold decrease in anti-Mullerian hormone (pg/mL) was associated with a 1.85-mm³ decrease in gray matter volume over the follow-up period. The researchers' longitudinal analyses of participants' clinical outcomes is ongoing.

NEW ORLEANS—Levels of anti-Mullerian hormone, a marker of the perimenopausal period, are associated with total gray matter volume and disability in patients with multiple sclerosis (MS), independent of chronological age and disease duration, according to data presented at the ACTRIMS 2016 Forum. The study also indicates that women with MS have no reduction in follicular reserve, compared with healthy women, and therefore have normal fertility.

Women with MS tend to have a more benign initial course than men with MS do, but the former often transition to secondary progressive disease near the time of menopause. To date, research has not clarified whether ovarian decline contributes to the accumulation of disability in women with MS.

Jennifer S. Graves, MD, PhD, a neurologist at the University of California, San Francisco Medical Center, and colleagues initiated a study to determine whether ovarian decline, as measured by levels of anti-Mullerian hormone, is associated with clinical disability or brain atrophy in women with MS. They examined 412 women with MS (mean age, 42.6) and 180 healthy controls (mean age, 44) from a longitudinal research cohort that had as many as 10 years of clinical and MRI follow-up. The investigators measured anti-Mullerian hormone levels in batch using a highly sensitive enzyme-linked immunosorbent assay on plasma samples from baseline, year 3, year 5, and years 8 to 10. They analyzed the data with logistic, linear, and mixed-model regression techniques, with adjustments for age, disease duration, smoking, race, ethnicity, vitamin D level, disease modifying therapy, birth control, and hormone replacement therapy as appropriate.

Jennifer S. Graves, MD, PhD

Dr. Graves and colleagues found that in models controlling for age, anti-Mullerian hormone levels were similar in women with MS and healthy controls. In a multivariable model of women with MS, including rigorous adjustments for age and disease duration, ovarian reserve (per twofold decrease in anti-Mullerian hormone pg/mL) was associated with total normalized gray matter volume (β = -3.29 mm³) and MS Functional Composite z-scores (β = -0.060) at baseline. After adjustment for age, white matter volumes were also associated with anti-Mullerian hormone levels (β = -2.64 mm³) at baseline, but the association did not remain statistically significant after additional adjustments (β = -1.49 mm³).

Having undetectable levels of anti-Mullerian hormone (28% of subjects) was associated with 0.60-point higher Expanded Disability Status Scale score. In a multivariable random-intercept-random-slope model using all observations over time, a twofold decrease in anti-Mullerian hormone (pg/mL) was associated with a 1.85-mm³ decrease in gray matter volume over the follow-up period. The researchers' longitudinal analyses of participants' clinical outcomes is ongoing.

NEW ORLEANS—Levels of anti-Mullerian hormone, a marker of the perimenopausal period, are associated with total gray matter volume and disability in patients with multiple sclerosis (MS), independent of chronological age and disease duration, according to data presented at the ACTRIMS 2016 Forum. The study also indicates that women with MS have no reduction in follicular reserve, compared with healthy women, and therefore have normal fertility.

Women with MS tend to have a more benign initial course than men with MS do, but the former often transition to secondary progressive disease near the time of menopause. To date, research has not clarified whether ovarian decline contributes to the accumulation of disability in women with MS.

Jennifer S. Graves, MD, PhD, a neurologist at the University of California, San Francisco Medical Center, and colleagues initiated a study to determine whether ovarian decline, as measured by levels of anti-Mullerian hormone, is associated with clinical disability or brain atrophy in women with MS. They examined 412 women with MS (mean age, 42.6) and 180 healthy controls (mean age, 44) from a longitudinal research cohort that had as many as 10 years of clinical and MRI follow-up. The investigators measured anti-Mullerian hormone levels in batch using a highly sensitive enzyme-linked immunosorbent assay on plasma samples from baseline, year 3, year 5, and years 8 to 10. They analyzed the data with logistic, linear, and mixed-model regression techniques, with adjustments for age, disease duration, smoking, race, ethnicity, vitamin D level, disease modifying therapy, birth control, and hormone replacement therapy as appropriate.

Jennifer S. Graves, MD, PhD

Dr. Graves and colleagues found that in models controlling for age, anti-Mullerian hormone levels were similar in women with MS and healthy controls. In a multivariable model of women with MS, including rigorous adjustments for age and disease duration, ovarian reserve (per twofold decrease in anti-Mullerian hormone pg/mL) was associated with total normalized gray matter volume (β = -3.29 mm³) and MS Functional Composite z-scores (β = -0.060) at baseline. After adjustment for age, white matter volumes were also associated with anti-Mullerian hormone levels (β = -2.64 mm³) at baseline, but the association did not remain statistically significant after additional adjustments (β = -1.49 mm³).

Having undetectable levels of anti-Mullerian hormone (28% of subjects) was associated with 0.60-point higher Expanded Disability Status Scale score. In a multivariable random-intercept-random-slope model using all observations over time, a twofold decrease in anti-Mullerian hormone (pg/mL) was associated with a 1.85-mm³ decrease in gray matter volume over the follow-up period. The researchers' longitudinal analyses of participants' clinical outcomes is ongoing.

For the February podcast for The Journal of Community and Supportive Oncology, Editor-in-Chief Dr David Henry examines two Original Reports, one on a collaborative investigation by scientists and members of a social network into fluoroquinolone-related neuropsychiatric and mitochondrial toxicity and another on the prognostic value of complete remission with superior platelet counts in patients with acute myeloid leukemia. The Case Reports this month focus on rare tumors: in one case, it is a metastatic primary bladder adenocarcinoma for which a novel treatment approach prolonged survival; and in a second, an 18-year follow-up on a rare, indolent form of T-cell prolymphocytic leukemia. The Community Translations column features the novel MEK inhibitor, cobimetinib, which was approved last year in combination with the BRAF inhibitor, vemurafenib, for metastatic melanoma with BRAF V600E or V600K mutation. Dr Henry also discusses articles on new therapies for gastrointestinal cancers and on selected practice-changing presentations from the 2015 annual meeting of the San Antonio Breast Cancer Symposium in Orlando last year. 

Listen to the podcast below.

For the February podcast for The Journal of Community and Supportive Oncology, Editor-in-Chief Dr David Henry examines two Original Reports, one on a collaborative investigation by scientists and members of a social network into fluoroquinolone-related neuropsychiatric and mitochondrial toxicity and another on the prognostic value of complete remission with superior platelet counts in patients with acute myeloid leukemia. The Case Reports this month focus on rare tumors: in one case, it is a metastatic primary bladder adenocarcinoma for which a novel treatment approach prolonged survival; and in a second, an 18-year follow-up on a rare, indolent form of T-cell prolymphocytic leukemia. The Community Translations column features the novel MEK inhibitor, cobimetinib, which was approved last year in combination with the BRAF inhibitor, vemurafenib, for metastatic melanoma with BRAF V600E or V600K mutation. Dr Henry also discusses articles on new therapies for gastrointestinal cancers and on selected practice-changing presentations from the 2015 annual meeting of the San Antonio Breast Cancer Symposium in Orlando last year. 

Listen to the podcast below.

For the February podcast for The Journal of Community and Supportive Oncology, Editor-in-Chief Dr David Henry examines two Original Reports, one on a collaborative investigation by scientists and members of a social network into fluoroquinolone-related neuropsychiatric and mitochondrial toxicity and another on the prognostic value of complete remission with superior platelet counts in patients with acute myeloid leukemia. The Case Reports this month focus on rare tumors: in one case, it is a metastatic primary bladder adenocarcinoma for which a novel treatment approach prolonged survival; and in a second, an 18-year follow-up on a rare, indolent form of T-cell prolymphocytic leukemia. The Community Translations column features the novel MEK inhibitor, cobimetinib, which was approved last year in combination with the BRAF inhibitor, vemurafenib, for metastatic melanoma with BRAF V600E or V600K mutation. Dr Henry also discusses articles on new therapies for gastrointestinal cancers and on selected practice-changing presentations from the 2015 annual meeting of the San Antonio Breast Cancer Symposium in Orlando last year. 

Listen to the podcast below.

 

 

Person on a scale

 

A new analysis indicates that having a higher body weight and taller stature during adolescence may increase the risk of developing non-Hodgkin lymphoma (NHL).

Global rates of NHL have been on the rise in recent years, and research suggests that rising rates of obesity may be contributing to this trend.

With this in mind, investigators examined whether adolescent weight and height might be associated with the risk of developing NHL later in life.

They reported their results in Cancer.

The study included 2,352,988 subjects, ages 16 to 19, who were examined between 1967 and 2011. Their information was linked to the Israel National Cancer Registry, which included 4021 cases of NHL from 1967 through 2012.

The data showed that being overweight or obese in adolescence was associated with an increased risk of NHL later in life. When compared to adolescents of normal weight, the hazard ratio (HR) was 1.25 for subjects who were overweight or obese. The HR for underweight individuals was 0.98.

Being overweight or obese in adolescence was a significant predictor for marginal zone lymphoma (HR=1.70), primary cutaneous lymphoma (PCL, HR=1.44), and diffuse large B-cell lymphoma (DLBCL, HR=1.31). Excess weight was a borderline predictor for follicular lymphoma (HR=1.28).

“It is important to be aware that overweight and obesity are not risk factors only for diabetes and cardiovascular disease but also for lymphomas,” said study author Merav Leiba, MD, of the Sheba Medical Center in Israel.

Dr Leiba and her colleagues also observed an increased risk of NHL corresponding with increases in subjects’ height. When compared with the mid-range height category, shorter individuals had an HR of 1.25, and the tallest individuals had an HR of 1.28.

The strongest associations between taller height and NHL were observed for primary cutaneous lymphoma and diffuse large B-cell lymphoma. The HRs for the tallest group, compared to the shortest group, were 3.19 for PCL and 2.21 for DLBCL.

The investigators said additional research is needed to help explain the links between height, weight, and NHL.

 

 

Person on a scale

 

A new analysis indicates that having a higher body weight and taller stature during adolescence may increase the risk of developing non-Hodgkin lymphoma (NHL).

Global rates of NHL have been on the rise in recent years, and research suggests that rising rates of obesity may be contributing to this trend.

With this in mind, investigators examined whether adolescent weight and height might be associated with the risk of developing NHL later in life.

They reported their results in Cancer.

The study included 2,352,988 subjects, ages 16 to 19, who were examined between 1967 and 2011. Their information was linked to the Israel National Cancer Registry, which included 4021 cases of NHL from 1967 through 2012.

The data showed that being overweight or obese in adolescence was associated with an increased risk of NHL later in life. When compared to adolescents of normal weight, the hazard ratio (HR) was 1.25 for subjects who were overweight or obese. The HR for underweight individuals was 0.98.

Being overweight or obese in adolescence was a significant predictor for marginal zone lymphoma (HR=1.70), primary cutaneous lymphoma (PCL, HR=1.44), and diffuse large B-cell lymphoma (DLBCL, HR=1.31). Excess weight was a borderline predictor for follicular lymphoma (HR=1.28).

“It is important to be aware that overweight and obesity are not risk factors only for diabetes and cardiovascular disease but also for lymphomas,” said study author Merav Leiba, MD, of the Sheba Medical Center in Israel.

Dr Leiba and her colleagues also observed an increased risk of NHL corresponding with increases in subjects’ height. When compared with the mid-range height category, shorter individuals had an HR of 1.25, and the tallest individuals had an HR of 1.28.

The strongest associations between taller height and NHL were observed for primary cutaneous lymphoma and diffuse large B-cell lymphoma. The HRs for the tallest group, compared to the shortest group, were 3.19 for PCL and 2.21 for DLBCL.

The investigators said additional research is needed to help explain the links between height, weight, and NHL.

 

 

Person on a scale

 

A new analysis indicates that having a higher body weight and taller stature during adolescence may increase the risk of developing non-Hodgkin lymphoma (NHL).

Global rates of NHL have been on the rise in recent years, and research suggests that rising rates of obesity may be contributing to this trend.

With this in mind, investigators examined whether adolescent weight and height might be associated with the risk of developing NHL later in life.

They reported their results in Cancer.

The study included 2,352,988 subjects, ages 16 to 19, who were examined between 1967 and 2011. Their information was linked to the Israel National Cancer Registry, which included 4021 cases of NHL from 1967 through 2012.

The data showed that being overweight or obese in adolescence was associated with an increased risk of NHL later in life. When compared to adolescents of normal weight, the hazard ratio (HR) was 1.25 for subjects who were overweight or obese. The HR for underweight individuals was 0.98.

Being overweight or obese in adolescence was a significant predictor for marginal zone lymphoma (HR=1.70), primary cutaneous lymphoma (PCL, HR=1.44), and diffuse large B-cell lymphoma (DLBCL, HR=1.31). Excess weight was a borderline predictor for follicular lymphoma (HR=1.28).

“It is important to be aware that overweight and obesity are not risk factors only for diabetes and cardiovascular disease but also for lymphomas,” said study author Merav Leiba, MD, of the Sheba Medical Center in Israel.

Dr Leiba and her colleagues also observed an increased risk of NHL corresponding with increases in subjects’ height. When compared with the mid-range height category, shorter individuals had an HR of 1.25, and the tallest individuals had an HR of 1.28.

The strongest associations between taller height and NHL were observed for primary cutaneous lymphoma and diffuse large B-cell lymphoma. The HRs for the tallest group, compared to the shortest group, were 3.19 for PCL and 2.21 for DLBCL.

The investigators said additional research is needed to help explain the links between height, weight, and NHL.